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Chapter 1 
Introduction 
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Immunotherapy of cancer 
The immunotherapy of cancer is based on the assumption that the immune 
system can be stimulated to recognize cancer and eradicate tumor. The course of 
most human cancers indicates that natural protective immunity against cancer 
either is non existent or fails. Theoretical models of immune activation propose 
that the immune system has evolved to recognize self from non-self [Langman et 
al, 2000], and that immune activation is initiated when the immune system 
senses or recognizes danger [Matzinger, 2001]. According to these models, the 
immune tolerance that may exists for cancer cells has been hypothesized to 
develop due to predominant expression of self antigens on tumors or lack of 
recognition of non-self on tumors. Alternatively, tolerance may be due to lack of 
"danger" signals during the early development of cancer. The goal of cancer 
immunotherapy is to exploit the immune system in the battle against cancer. 
One of the approaches of immunotherapy consists of systemic administration 
of cytokines. Cytokines are soluble proteins involved in cellular communication, 
initially identified as products of cells of the immune system. Large scale 
production of cytokines by recombinant DNA technology has enabled the study of 
their anti-tumor efficacy. Interleukin (IL-)12 is a cytokine with important 
immunoregulatory functions and strong anti-tumor effects in animal models. 
Renal cell cancer is one of the few malignancies that has shown susceptibility 
to cytokine immunotherapy. While conventional chemotherapy has a low 
efficacy, with response rates of 15% at the best [reviewed by Ruiz et al, 2000], 
therapy with interferon (IFN) a., or the combination of IL-2 and IFN-a., with or 
without 5-fluorouracil, has resulted in response rates between 15 and 36%. 
[reviewed by Motzer et al, 2000; Atzpodien et al, 2000]. Still, effective treatment 
is not available for the majority of patients with metastatic disease, and 
therefore, new treatment strategies must be developed. 
Il-12: structure, production and receptors 
IL-12 was discovered 1989, and initially called "cytotoxic lymphocyte 
maturation factor" [Stern et al, 1990] or "natural killer (NK) cell stimulating 
factor" [Kobayashi et al, 1989]. IL-12 is composed of two disulfide-linked sub-
units with molecular weights of 35kDa (p35) and 40kDa (p40), respectively 
[Podlaski et al, 1992]. P35 and p40 are structurally unrelated and their genes 
have been mapped to separate chromosomes, i.e. 3p12-3q13.2 and 5q31-q33 
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[Sieburth et al, 1992]. The p40 sequence is not homologous to any other known 
cytokine and has sequence homology with the extra-cellular domain of the Il-6 
receptor [Gearing et al, 1991], whereas the p35 sub-unit has structural 
similarities with IL-6 itself and granulocyte-colony- stimulating factor (G-CSF) 
[Merberg et al, 1992]. Therefore it has been proposed that Il-12 resembles a 
secreted, disulfide-linked complex of a cytokine with its own receptor. Various 
cells produce Il-12, such as phagocytic cells, dendritic cells and B lymphocytes 
[reviewed by Trinchieri 1996; Heuf/er eta/, 1996; Schultze eta/, 1999]. 
The production of Il-12 is strongly stimulated by infectious pathogens and 
their products [D'Andrea et al, 1992; Sato et a/, 1996]. Additionally, CD40 
ligand-receptor interactions, between T lymphocytes and antigen presenting 
cells, result in the production of IL-12 by the latter [Shu eta/, 1995]. 
High affinity receptors for ll-12 are composed of two sub-units, designated 
~1 and ~2 [Presky et al, 1996]. In humans, each subunit binds Il-12 with only 
low affinity, while co-expression is required for the generation of high affinity 
binding. The ~2 subunit is more restricted in its distribution [Presky eta/, 1996]. 
Dual expression of the sub-units has been shown on NK- and T cells. Several 
other cells, such as neutrophils, dendritic cells, B lymphocytes and eosinophils, 
express the ~1 sub-unit and were shown to respond to Il-12 in-vitro [Desai eta/, 
1992; Nutku et al, 2001; Nagayama et a/, 2000; Airoldi et al, 2000]. Signal 
transduction through the high affinity receptors on lymphocytes involves tyrosine 
phosphorylation of the Tyk2 and Jak2 kinases and of the transcription factors 
STAT3 and STAT4 [Bacon et al, 1995a and 1995b; Jacobson eta/, 1995]. 
Biological activities in vitro 
IL-12 has several biological properties that may have anti-tumor effects, but 
the most important one is probably enhancement of the cellular immune 
reactivity by directing T helper cell differentiation in favor of T helper type 1 
(Th1) responses [Germann et al, 1993; Trinchieri, 1996; Heufler eta/, 1996]. 
Th1 cells produce IFN-y and IL-2 and promote the cell mediated immune 
response, that is considered the most important effector mechanism in the 
eradication of tumors. IL-12 promotes the commitment of naive T cells, during 
their encounter with antigen, into Thl cells, and in addition, stimulates maximum 
secretion of IFN-y by Thl cells and promotes the activation of memory Th1 cells 
[Manetti et al, 1993; Germann et al, 1993; Heufler et a/, 1996]. Another 
important property of ll-12 is the ability to strongly stimulate activated T and NK 
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cells to produce IFN-y. In fact, IFN-y is considered the most important mediator 
of the biological effects of Il-12 administration in vivo [Wu et al, 1993; Brunda 
et al, 1995a; Nastala et al, 1994]. In addition, Il-12 induces other cytokines, 
such as tumor necrosis factor-a (TNF-a), granulocyte-macrophage-colony-
stimulating factor (GM-CSF), Il-2, Il-3, Il-8 and Il-10, that can regulate 
activation and migration of various immune cells [Trinchieri, 1996]. In vitro, Il-
12 also stimulates NK- and lymphokine activated killer cell non-specific lytic 
activity against tumor cells in culture [Kobayashi et al, 1989] and promotes 
activation of specific cytolytic T cells [Gately et al, 1992]. 
Animal studies 
IL-12 administration had potent anti-tumor effects in several murine tumor 
models, including murine renal cell cancer [reviewed by Brunda et al, 1996]. IL-
12 was administered either systemically by intra-peritoneal injection or locally, 
by fibroblasts genetically engineered to produce IL-12. IL-12 administration 
resulted in complete tumor regression of established tumors and their 
metastases, reduced spontaneous metastases and induced resistance to re-
challenge with the same tumor after initial cure. In distinct tumor models, the 
mechanisms responsible for the anti-tumor effect were different, i.e. depended 
on the model studied. Cellular depletion studies and studies in knockout mice 
have demonstrated that NK cells , CD8+ and CD4+ T cells, or a combination of 
these are most frequently involved in the anti-tumor effect in animal models 
[Brunda et al, 1996]. In addition, it was shown, that although IFN-y was required 
for optimal anti-tumor responses in most models, IFN-y in itself was not sufficient 
to mediate the anti-tumor effects [Brunda et al, 1995a]. IL-12 was also shown to 
inhibit tumor associated angiogenesis [Voest et al, 1995; Sgadari et al, 1996]. 
Pre-clinical studies with human IL-12 were performed in severe combined 
immunodeficiency (SCID) mice. Transfer of human effector cells, such as NK and 
cytotoxic T cells, in combination with treatment with human IL-12 resulted in 
prolonged survival of tumor bearing mice [Cesano et al, 1994, 1995]. The anti-
tumor efficacy of IL-12 has been compared with other cytokines with established 
efficacy in cancer. IL-12 had greater activity than IL-2 and IFN-a in mouse 
models of renal cell cancer as IL-2 and IFN-a only induced growth retardation, 
while IL-12 actually induced tumor regression [Brunda et al, 1995b] 
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Outline of the thesis 
Il-12 has a number of immunoregulatory properties indicating its therapeutic 
potential against cancer. The encouraging anti-tumor effects, observed in a 
variety of animal tumor models, have stimulated the development of Il-12 as a 
single agent for systemic cytokine therapy of cancer in humans. Metastatic renal 
cell cancer is one of the few human cancers that are more responsive to 
immunotherapy than to conventional cytotoxic therapies. Therefore, a phase I 
study of Il-12 was performed in patients with advanced renal cell cancer. The 
choice of schedule and route of administration were based on experiments in 
cynomolgus monkeys. Il-12 in s.c. doses of 0.1 to 1.0 Jlg /kg /day, three times a 
week, was shown to modulate immune activity without provoking substantial 
toxicity in these animals. 
The objective of the study described in chapter 2 was to evaluate the safety 
and tolerability of subcutaneous IL-12 in humans and establish the 
pharmacokinetic profile. The observation of a non-linear relationship between 
dose and drug exposure in animal models formed the rationale to study the 
effects of a single and multiple doses of Il-12. In chapter 3 the 
immunomodulatory activities of IL-12 in humans are described in detail, with 
emphasis on the induction of secondary cytokines and the effects on circulating 
leucocyte subset counts. Based on the observation that side effects decreased 
upon repeated injections of IL-12, we specifically studied whether or not 
immunomodulatory effects were downregulated in the course of multiple IL-12 
injections with special attention for the role of the immunosuppressive cytokine 
IL-10. 
Chapter 4 describes a study of the effect of IL-12 on fibrinolysis and 
coagulation in humans. This study was performed because several bleeding 
episodes were reported in simultaneously performed clinical studies, whereas 
studies in mice and non-human primates had shown that IL-12 induced 
activation of coagulation and fibrinolysis. 
Il-12 is a strong pro-inflammatory cytokine. Studies in patients and 
experimental animals have demonstrated that endogenously produced IL-12 
plays an important role in the toxic sequel of sepsis and endotoxemia. In these 
situations, excessive activation of various components of the inflammatory 
cascade contributes to the development of tissue injury and mortality. In chapter 
5 we describe the in-vivo effects of different doses of subcutaneous Il-12 on 
components of the inflammatory cascade. We specifically addressed the 
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degranulation of neutrophils and the formation of secretory phospholipase Az, a 
regulatory enzyme in the formation of eicosanoids. 
The study described in chapter 2 was one of four phase I studies, that were 
simultaneously performed in Europe and the US. Subsequent phase II studies in 
patients with advanced renal cell cancer and ovarian cancer demonstrated 
disappointing anti-tumor effects. The results described in chapter 3, together 
with other pharmacodynamic studies, indicate that the lack of efficacy was 
accompanied by, and probably related to, declining biological effects of IL-12 in 
the course of repeated administrations at doses approaching the maximum 
tolerated dose (MTD). Nevertheless, IL-12 remains a promising immuno-
therapeutic agent because recent cancer vaccination studies in animal models 
and humans have demonstrated its powerful adjuvant properties. Chapter 6 
reviews the adjuvant properties of IL-12 and delineates how the immune-
regulatory properties of IL-12 described in the previous chapters may contribute 
to the adjuvant effects. In addition, it is discussed how the studies presented in 
this paper, together with other clinical studies of systemic IL-12, indicate that IL-
12 may exert optimal adjuvant effects only at low dose levels. Finally, the future 
perspectives of IL-12 in the treatment of cancer are addressed. 

Chapter 2 
A phase I study of subcutaneously administered recombinant 
human Il-12 in patients with advanced renal cell cancer 
Adapted from: 
Phase I study of subcutaneously administered recombinant human interleukin 12 
in patients with advanced renal cell cancer 
Johanna E. A. Portielje, Wim H. J. Kruit, Martin Schuler, Joachim Seck, Cor H. J. 
Lamers, Gerrit Stater, Christoph Huber, Maureen de Boer-Dennert, Ashok Rakhit, 
Reinder L. H. Solhuis and Walter E. Aulitzky 
Clinical Cancer Research 1999; 5: 3983-3989 
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Abstract 
A phase I study was conducted to characterize the maximum tolerated dose 
(MTD), dose limiting toxicity (DLT) and pharmacokinetics of a single dose 
followed by three times weekly subcutaneous (s.c.) injections of recombinant 
human interleukin 12 (rHuiL-12). 
The study encompassed 28 patients with advanced renal cell carcinoma. 
RHuiL-12 was administered on day 1, followed by an observation period of 7 
days. Starting on day 8, repeated s.c. injections were administered 3 times a 
week, for 2 weeks. 
The MTD of the initial injection was evaluated at dose levels of 0.1, 0.5 and 
1.0 ug/kg. DLT was observed at 1.0 ug/kg and consisted of fever, perivasculitis 
of the skin and leucopenia. The MTD of the subsequent repeated injections after 
1 week of rest was studied at dose levels 0.5, 1.0 and 1.25 ug/kg. DLT at 1.25 
ug/kg comprised deterioration of performance status, fever, vomiting, mental 
depression and leucopenia. Other notable toxicities were oral mucositis and 
elevation of hepatic enzymes. Fever, leucopenia and elevation of hepatic 
enzymes were more severe after the initial injection than after repeated injecti-
ons at the same dose level. 
At dose level 0.5 ug/kg, the mean area under the plasma concentration-time 
curve decreased from 7.4 ng x h/ml after the first injection to 3.3 ng x h/ml 
(p=0.034) after repeated administrations, and at dose level 1.0 ug/kg, from 31.8 
ng x h/ml to 6.0 ng x h/ml (p=0.041). One patient had a partial response and 
seven patients had stable disease. 
Conclusion: The MTD of a single s.c. injection of rHuiL-12 was 0.5 ug/kg and 
the MTD of 3 subsequent administrations per week was 1.0 ug/kg. In comparison 
with a single administration, the 3 times weekly administrations at the same 
dose level were accompanied with a milder pattern of side effects and a 
reduction of the area under the plasma concentration-time curve. 
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Introduction 
Interleukin 12 (IL-12) is a heterodimeric cytokine with immunoregulatory 
functions. It stimulates the proliferation and activation of T lymphocytes and 
natural killer cells [Kobayashi et al, 1989; Perussia et al, 1992] and induces the 
production of IFN-y by these cells [Kobayashi et al, 1989; Chan et al, 1991]. IL-
12 promotes T- helper type 1 responses [Manetti et al, 1993; Wu et al, 1993], 
including the commitment of naive helper T cells to the T- helper type 1 deve-
lopmental pathway, while inhibiting T-helper type 2 development and function, 
thereby promoting cellular immunity [Scott, 1993]. Additionally, IL-12 can inhibit 
tumor-associated angiogenesis [Voest et al, 1995; Sgadari et al, 1996]. The 
antitumor effects of IL-12 have been evaluated in a large number of murine tu-
mor models and more recently in nonhuman primate tumor models [Brunda et 
al, 1993; Nastala et al, 1994; Fujiwara et al, 1996; Sarmiento et al, 1994; Bree 
et al, 1994]. Cures and long term survival were seen in murine renal cell 
carcinoma (RCC) at doses that resulted in mild toxicities. These results show that 
IL-12 has important immunomodulatory and anti-tumor effects in animal models. 
Clinical experience with IL-12 in humans is limited. Metastatic RCC appears to be 
more responsive to immunomodulatory treatment than to conventional cytotoxic 
chemotherapy. However, despite progress in treatment, overall prognosis 
remains poor and effective immunotherapies are needed [Motzer et al, 1996]. 
Therefore, we performed a Phase I study of subcutaneous (s.c.) administration of 
recombinant human interleukin 12 (rHuiL-12) in patients with RCC. 
The choice of schedule and route of administration were based on 
experiments in cynomolgus monkeys (Hoffmann La Roche, personal 
communication). IL-12 in s.c. doses of 0.1 to 1.0 ;.tg/kg per day, three times a 
week, were shown to modulate immune activity without provoking substantial 
toxicity in these animals. The observation of a nonlinear relationship between 
dose and drug exposure formed the rationale to study the effects of a single and 
multiple doses of IL-12. The purpose of the study was to investigate the toxicity 
and pharmacokinetics of a single s.c. administration of rHuiL-12 and of a 
schedule of 3 s.c. administrations per week for 2 weeks, started one week after 
this single s.c. injection. 
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Patients and Methods 
Patient selection 
Patients had histologic proof of RCC with measurable locally advanced or 
metastatic disease. Patients were between 18 and 75 years of age, had a WHO 
performance score of 0 to 1, a life expectancy > 4 months, adequate renal 
function (serum creatinine < 1.5 times normal), adequate hepatic function 
(normal serum bilirubine, serum ALT and/or aspartate-aminotransferase < 2.5 
times normal, serum alkaline phosphatase < 2.5 times normal ), normal serum 
calcium, serum hemoglobin > 10 g/dl, white blood count > 3x109/liter, gra-
nulocytes > 2x109/liter, platelets > 75x109/liter and normal pulmonary function. 
They had not received more than one previous immunotherapy. All former 
therapies were ended at least 6 weeks prior to start of treatment with rHuiL-12. 
Patients did not use systemic corticosteroids. Patients with brain or leptome-
ningeal metastases or major fluid effusions (e.g. ascites, pleural effusions) were 
excluded. Patients with major concurrent systemic disease, an organ graft or a 
prior history of other malignancy were excluded as were patients known to be 
seropositive for HIV or Hepatitis B surface antigen. All patients gave written 
informed consent. 
rHuiL-12 
rHuiL-12 (Ro 24-7472) was supplied by Hoffmann La Roche, Nutley, NJ, 
U.S.A and administered by s.c. injection. The first injection was an in-hospital 
treatment. Subsequent injections were given on an outpatient basis. 
Study design 
The study was an open label non-randomized Phase I dose escalation trial 
carried out in two European cancer centers to evaluate the safety and tolerability 
of an initial single injection of rHuiL-12 as well as the safety and tolerability of 
repeated s.c. injections administered in treatment cycles of 2 weeks with three 
injections per week. Pharmacokinetics and pharmacodynamics were studied 
simultaneously. The treatment protocol was approved by the ethics board of the 
participating institutions. 
Treatment schedule and follow up 
On day 1 a single s.c. injection of rHuiL-12 was given, followed by an 
observation period of 7 days. Subsequently, on day 8 repeated injections were 
started, with rHuiL-12 s.c., three times a week, for 2 weeks. After a 2-week rest 
period repeated injections were resumed with an identical schedule. Tumor 
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volume was assessed after 2 months of treatment. Patients who did not 
experience tumor progression or DLT could be treated with additional cycles. The 
dose of rHull-12 was calculated per kilogram (kg) body-weight, where 80 kg 
was taken as the maximum multiplication factor. 
The MTD was defined as one dose level below the dose that causes DLT, i.e. 
the dose that causes drug-related grade 3 or 4 toxicity, with the exception of 
lymphopenia, in one third of patients. Dose escalation for the initial single 
injection was decided upon the toxicity encountered during the week of observa-
tion that followed, until repeated dosing was started from day 8 onwards. Toxi-
city was assessed using the National Cancer Institute Common Toxicity Criteria. 
To define the MTD, cohorts of three patients were entered at each dose level 
until a grade 3 or 4 toxicity occurred; for these and subsequent dose escalation 
levels, three more patients were entered. If more than one patient experienced 
drug-related grade 3 or 4 toxicity, three more patients were entered at the 
previous dose level. As long as the MTD for the initial single injection had not 
been reached, the dose of rHuiL-12 for repetitive administrations was identical 
with the initial dose. 
Once the MTD was reached for the initial single dose, this dose was fixed in 
all subsequent patients. To define the MTD for repeated injections, the toxicity 
encountered during the first two cycles (8th until 64th day) were evaluated. 
Further dose escalation steps were carried out as previously described. 
Before start of the study, all considered patients underwent a complete 
medical history and physical examination, electrocardiography, hematology and 
blood chemistry tests, dipstick urinalysis, pulmonary function test with carbon 
monoxide (CO) diffusion capacity and measurements of study parameters by 
chest X-ray and Computerized tomography scan. 
After the single initial injection, patients had physical examination and 
complete blood counts daily and serum chemistry and urinalysis were repeated 
on days 1 and 2. During the repetitive injections, vital signs and complete blood 
counts were assessed after all drug administrations and serum chemistry and 
urinalysis were repeated twice a week. Pulmonary function tests were performed 
on days 12, 19 and 26. Study parameters were measured by chest X-ray and 
Computerized tomography scan after each treatment period of 2 months. 
Pharmacokinetic sampling and data analysis 
Pharmacokinetic parameters were calculated from serum concentrations of 
rHuiL-12 in blood samples taken before and 4, 6, 8, 10, 12, 18, 24, 30, 36, 48, 
72 and 96 hours after the single initial injection. During the repetitive injections, 
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blood samples were taken on day 15 and 17 prior to drug administration, on day 
19, prior to and 4, 6, 8, 10, 12, 18, 24, and 36 hours after drug administration 
and on day 26. 
Serum concentrations of rHuiL-12 were measured by a method of antibody 
capture followed by a cell proliferation assay [Motzer et al, 1998]. This assay has 
a lower limit of detection of 50 pg/ml. 
Individual patients' plasma concentration-time data were analysed using the 
Siphar software package (version 4.0; SIMED, Creteil, France) by 
noncompartmental analysis. The area under the plasma concentration-time curve 
(AUC) for rHuiL-12 was calculated by the linear trapezoidal rule up to the last 
sampling point with detectable levels (C), with extrapolation to infinity 
(AUCa-'ooefio~to) by the equation AUC + Cjk,, , where ke1 represents the terminal 
disposition rate constant. The latter term was calculated from the slope of the 
data points in the final log-linear part of the concentration-time curve by weighed 
(1/y) least-squares linear regression analysis. Maximum plasma concentrations 
(Cm,J and the time to maximum concentration (T mox) were estimated by visual 
inspection of the semilogarithmic plot of the concentration-time curve. The 
terminal disposition half-life (tv,) was calculated by dividing ln2 by ke1 • 
To test parameter differences for statistical significance among treatment 
courses, a two-tailed paired Student's t-test was performed. Probability values of 
less than 0.05 were regarded as statistically significant. All statistical calculations 
were performed using Number Cruncher Statistical System (NCSS, version S.X; 
Dr. Jerry Hintze, Kayesville, UT, USA) and STATGRAPHICS Plus (version 2; 
Manugistics Inc., Rockville, MD, USA). 
Results 
Patient population 
The characteristics of the 28 patients who participated in the study are 
given in Table 1. Twenty patients were male. The median age was 56 years. 
Twenty-seven patients had undergone nephrectomy and 13 of them received 
surgical treatment only. There were nine patients pretreated with immu-
notherapy (IFN-y, IL-2 or a combination of IFN-()( and IL-2 with or without 
lymphokine-activated killer cells), two patients with chemotherapy and four 
patients with immunotherapy and chemotherapy. The results of three patients 
were excluded from analysis: One patient erroneously received an overdose at 
the first injection without major sequela. In two patients, both with a history of 
24 • Chapter 2 • 
atrial fibrillation, this arrhythmia recurred after the first single injection. These 
patients were removed from the study. Twelve patients received one treatment 
cycle, nine patients received two cycles and four patients had more than two 
cycles with a maximum of six. 
Table 1. Patient characteristics 
Number of patients 28 
Median age (years) 56 (41-70') 
Gender (male/female) 20/8 
Performance status 
Karnofsky 100% 15 
90% 9 
80% 4 
Previous therapy 
Surgical only 13 
Immunotherapy 9 
Chemotherapy 2 
Chemo- and immunotherapy 4 
Median duration of disease (months) 38 (1-264) 
Disease status 
Locally advanced 1 
Metastatic 27 
¥ Results are given in numbers; a range is shown in parentheses. 
Side effects and laboratory abnormalities 
Common side effects and laboratory abnormalities observed after the first, as 
well as after repeated injections of rHulL-12, were fever and flu-like symptoms 
(chills, sweating, headache, myalgia), anorexia1 nausea, vomiting, fatigue, 
leucopenia, lymphopenia, granulopenia, anemia, thrombopenia, hypocalcemia 
and elevation of hepatic enzymes. Oral mucositis, reduction of pulmonary CO 
diffusion capacity and hyponatremia mainly occurred after repeated injections. 
Fever sometimes persisted for several days after discontinuation of rHu!L-12. 
Table 2. Toxicity profile initial single injection (part 1) 
Dose level Hemoglobin Leukopenia Granulopenia Lymphopenia Thrombopenia 
(no of patients) 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 
0.1 ~g/kg (3) 0 0 0 0 1 1 0 0 1 0 0 0 0 2 1 0 0 0 0 0 
0.5 [tg/kg {6) 3 0 0 0 0 1 1 0 0 1 0 0 1 5 0 0 0 0 0 0 
1.0 [tg/kg (4) 3 0 0 0 0 3 1 0 1 2 0 0 1 2 0 1 4 0 0 0 
0.5 ~g/kg (12)* 2 0 0 0 3 2 3 0 3 2 3 0 3 5 2 1 2 0 0 0 
*After defining MTD for the initial Injection, the additional patients enrolled to define MTD for repeated injections received 
their initial injection at a dose of 0.5 rtg/kg 
Table 3. Toxicity profile initial single injection (part 2) 
Dose level Fever Fatigue Headache Nausea Vomiting 
(no of patients) 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 
0.1 ~g/kg (3) 1 0 0 0 1 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 
0.5 [tg/kg (6) 1 5 0 0 2 1 0 0 0 1 0 0 0 0 0 0 0 0 0 0 
1.0 ~g/kg (4) 0 3 1 0 1 3 0 0 2 0 0 0 3 0 0 0 2 0 0 0 
0.5 [tg/kg (12)* 3 9 0 0 1 1 0 0 6 0 0 0 4 0 0 0 2 1 0 0 
*After defining MTD for the Initial injection, the additional patients enrolled to define MTD for repeated injections received 
their initial injection at a dose of 0.5 ~g/kg 
Table 4. Toxicity profile initial single injection (part 3) 
Liver Hypo-
Dose level Mucositis Skin Diarrhea Pulmonary enzyems natremia 
(no of patients) 1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 
0.1 fl9/kg (3) 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 
0.5 fl9/kg (6) 0 0 0 0 0 0 0 0 0 0 0 0 3 1 0 2 0 0 
l.Oflg/kg (4) 0 1 0 0 0 1 0 0 0 0 0 0 2 2 0 0 0 0 
0.5 !19/kg (12)* 0 0 0 0 0 0 0 1 0 0 0 0 2 1 0 0 2 0 
*After defining MTD for the initial injection, the additional patients enrolled to define MTD for repeated injections received 
their initial injection at a dose of 0.5 ft9/kg 
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Determination of the MTD for the single initial dose 
The dose levels studied for the initial single dose were: 0.1 ~g/kg, 0.5 ~g/kg 
and 1.0 ~g/kg. Tables 2-4 present the side effects and their grading at these 
dose levels. 
Three patients received a single initial rHuiL-12 dose of 0.1 ~g/kg. No grade 
3 toxicities were observed. On dose level 0.5 ~g/kg, six patients were treated 
and one developed a grade 3 leucopenia. 
Of the four patients who received 1.0 ~g/kg, three developed DLT. One 
patient had a grade 3 leucopenia with grade 3 fever and one experienced a grade 
2 leukopenia that lasted 10 days, necessitating delay of the repetitive injection 
cycle. The third patient developed an erythema of the skin, which persisted for 8 
days. Histology of the lesions showed a perivasculitis. Consequently, 0.5 ~g/kg of 
rHu!L-12 was regarded as MTD for the initial single dose. 
Therefore, the 12 patients, who were subsequently enrolled to define the 
MTD of repetitive injections, had their first injections fixed at a dose of 0.5 ~g/kg. 
The side effects of these 12 patients are displayed in the bottom lines of Table 2. 
Of note, three of 12 patients experienced grade 3 leuco- and granulopenia. 
Determination of the MTD for the repetitive administration cycles 
The dose levels studied for the repetitive administration cycles were: 0.5 
~g/kg, 1.0 ~g/kg and 1.25 ~g/kg. In Tables 5-7, the toxicities according to these 
dose levels are shown. The worst observed toxicities observed in the first two 
treatment cycles were analysed. 
Six patients, who had received a single initial dose of rHuiL-12 at 0.5 ~g/kg 
received the same dose from day 8 onwards, three times a week. Because three 
of the 12 additional patients at the initial single dose of 0.5 ~g/kg experienced 
grade 3 leuko- and granulopenia, we decided to extend our experience at this 
dose level with repeated injections. Hence, nine patients received repeated 
injections, three times per week, at 0.5 ~g/kg. Only one developed a grade 3 
granulopenia during repeated administrations. These nine patients had a 
reduction of certain side effects and laboratory abnormalities (fever, leucopenia 
and elevation of hepatic enzymes) when the single initial injection was compared 
with the repeated injections (tables 5-7). This effect was also observed at 
consecutive higher dose levels. The next three patients received repeated 
injections at 1.0 ~g/kg without grade 3 or 4 toxicities. However, at a dose of 
1.25 ~g/kg, four of four patients exhibited DLT: All had grade 3 progressive 
fatigue with deterioration of performance status. 
Table 5. Toxicity profile repeated injections, worst of cycles 1 and 2 (part 1) 
Dose level Hemoglobin Leukopenia Granulopenia Lymphopenia Thrombopenia 
(no of patients) 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 
0.5 flQ/kg {9) 3 0 0 0 5 3 0 0 3 2 1 0 4 3 1 0 0 0 0 0 
1.0 flQ/kg {5) 2 0 0 0 2 1 0 0 3 0 0 0 0 5 0 0 0 0 0 0 
1.25 flQ/kg (4) 4 0 0 0 1 1 1 0 1 2 0 0 0 2 2 0 0 1 0 0 
Table 6. Toxicity profile repeated injections, worst of cycles 1 and 2 (part 2) 
Dose level Fever Fatigue Headache Nausea Vomiting 
(no of patients) 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 
0.5 flQ/kg {9) 3 4 0 0 5 0 0 0 3 1 0 0 4 0 0 0 4 0 0 0 
1.0 flQ/kg {5) 0 3 0 0 2 3 0 0 1 0 0 0 1 1 0 0 1 1 0 0 
1. 25 flQ/kg ( 4) 0 2 0 1 0 0 4 0 1 1 0 0 1 1 1 0 1 1 1 0 
Table 7. Toxicity profile repeated injections, worst of cycles 1 and 2 (part 3) 
Dose level Mucositis Pulmonary Liver enzymes Hyponatremia Hypocalcemia 
(no of patients) 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 
0.5 flQ/kg (9) 2 1 0 0 1 0 0 0 2 0 0 0 4 1 0 0 1 0 0 0 
1.0 flQ/kg (5) 2 1 0 0 2 1 0 0 4 0 0 0 2 1 0 0 1 1 0 0 
1.25 f!Q/kg (4) 2 2 0 0 1 1 0 0 2 1 0 0 2 2 0 0 1 0 0 0 
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One patient had grade 3 leucopenia and grade 4 fever, one patient had grade 
3 vomiting and nausea and one patient developed grade 3 psycho-neurotoxicity 
(a mental depression persisting for weeks after discontinuation of rHuil-12). As 
indicated in the protocol, more patients were subsequently entered at the 
previous dose level of 1.0 ~g/kg. In two additional patients no grade 3 or 4 
toxicity was observed. Added to the 3 patients earlier enrolled on this dose level, 
a total of five patients were treated with repeated injections at 1.0 ~g/kg. 
Because none suffered grade 3 or 4 adverse event, we declined from 
entering a sixth patient. Consequently, 1.0 ~g/kg of rHuil-12 was regarded as 
MTD for the repeated injections. 
Unrelated side effects 
Five patients developed complications unrelated to the study medication. In a 
patient that died of ventricular fibrillation, 11 days after the last rHull-12 
administration, autopsy showed extensive coronary atherosclerosis. 
A patient with a history of myocardial infarction had congestive heart failure. 
Of two patients with retroperitoneal lymphnode metastasis, one developed 
hydronephrosis and renal insufficiency and the other developed extensive deep 
venous thromoosis. Finally, a patient had gastrointestinal bleeding, due to 
duodenal tumor invasion. 
Tumor response 
Tumor response could be evaluated in 22 patients. A partial response, which 
lasted 4 months, was observed in a patient treated with repeated injections at 
dose level 0.5 ~g/kg. At study entry, the patient had local tumor recurrence and 
bone metastasis, 5 months after diagnosis of RCC and nephrectomy. He had not 
received prior systemic treatment. Seven Patients had stable disease that lasted 
between 2 and 6 months. All other patients had progressive disease. Sudden 
death and cardiac failure impeded evaluation of response in two patients and in 
another patient who only received a first dose of ll-12, evaluation was omitted. 
Pharmacokinetics 
Results of the pharmacokinetic studies are shown in Table 8. Samples for 
pharmacokinetic analysis, after the initial injection and subsequent injections, 
could be obtained from all 13 patients that were enrolled to define the MTD for 
the initial injection. From 6 additional patients, entered to define the MTD of 
repeated injections, samples after the initial injection at 0.5 ~g/kg could be 
analysed. At the 0.1 ~g/kg dose level, serum concentrations of rHull-12 were 
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below the assay's detection limit, after the initial single injection as well as after 
repeated injections. After an initial injection of 0.5 ~g/kg, serum rHuiL-12 increa-
sed to a mean level of 362 pgjml (Cmaxl- Peak levels of rHuiL-12 were reached at 
a mean of 9.67 hours (Tmax) after administration. 
Table 8. Pharmacokinetic data 
Mean (± SD) pharmacokinetic parameters at dose levels 0,5 ~g/kg and 
1.0 ~g/kg on days 1 and 19 
0.5/0.5 
Unit Day 1 Day 19 
n = 12 n=4 
Tmax h 9.7 (5) 9.5 (2.2) 
TY2 h 9.4 (3.5) 7.9 (1.6) 
Cmax pg/ml 362 (214) 255 (200) 
AUC ng x t/ml 7.4 (5.4)* 3.3 (1.6)* 
* Pvalue: 0.034 
# Pvalue: 0.041 
¥ n = 1 
Cmax: maximum plasma concentration 
T max: time to maximum concentration 
1.0/1.0 
Day 1 Day 19 
n=4 n=2 
17 (7) 4 (0) 
12.1 (3.6) 4.9 (-)' 
1131 (1051) 376 (49) 
31.8 (22.3) # 6 (2.4)' 
AUC: Area under the plasma concentration-time curve extrapolated to infinity 
Tv,: terminal disposition half life 
The mean half life (T,h) of rHull-12 was 9.36 hours. Mean Cmax, Tmax and T,h 
for repeated administrations at the 0,5 ~g/kg dose level did not differ 
significantly from the results after the initial injection. However, after repeated 
dosing of rHuiL-12, a considerable decrease of 55% in serum AUC was observed. 
The mean AUC of 7.43 ng x h/ml after the initial injection dropped to a mean 
AUC of 3.33 ng x h/ml after the last injection of the first cycle of repeated 
administration. This difference was highly significant (p=0.034). After an initial 
injection of 1.0 ~g/kg, mean Cmax was 1131 pg/ml, with a mean Tmax of 17 hours 
and a mean Tv, of 12.1 hours. These values did not differ significantly when 
measured after repeated injections. However, at this dose level, a significant 
decrease of 80% in serum AUC could be demonstrated as well, when comparing 
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the AUC after repeated injections with the AUC after the initial injection 
(p;0.041). In none of the patients could the development of antibodies to rHu-
IL-12 be detected during treatment. 
Discussion 
The primary objective of this Phase I study was to define the MTD of an initial 
single s.c. administration of rHuiL12 and of subsequent repeated doses and to 
study pharmacokinetics. The MTD of the initial single injection was 0.5 !!g/kg, 
whereas the MTD of the repeated administrations was 1.0 !!g/kg. DLTs of the 
single injection consisted of fever, perivasculitis of the skin and leucopenia. DLTs 
of repeated injections were progressive fatigue and deterioration of performance 
status, mental depression/ nausea, vomiting and leucopenia. 
The MTDs are comparable with those reported in other Phase I studies 
[Motzer et al, 1998; Atkins et al, 1997]. In a trial that compared a fixed, s.c., 
once a week dose scheme with an up-titration schedule of IL-12, the MTD's were 
1.0 and 1.5 !!g/kg, respectively and DLTs were elevation of transaminase 
concentration, pulmonary toxicity and leucopenia [Motzer et al, 1998]. In 
another trial, with IL-12 administered by i.v. injection for 5 days a week, after an 
initial injection 2 weeks earlier, DLT consisted of liver function abnormalities and 
oral mucositis and MTD was 0.5 !!g/kg [Atkins et al, 1997]. In contrast, we did 
not encounter hepatotoxicity as a dose limiting adverse event. 
The toxicity profile that we observed resembles that encountered in other studies 
[Motzer et al, 1998; Atkins et al, 1997; Bajetta et al, 1998], but two patients 
suffered side effects not earlier described in association with IL-12 therapy. One 
patient, who had no psychiatric history, experienced mental depression, 
necessitating antidepressive medication. Although similar complaints have not 
been attributed to treatment with IL-12 thusfar, the use of other cytokines, such 
as IL-2 [Denicoff et al, 1987] and IFN-a [Renault et al, 1987], has induced 
mental depression and a variety of other neuropsychiatric complaints. Another 
patient developed erythema of the skin and histological examination showed a 
perivasculitis. In a pilot study at 0.5 ~g/kg, a skin rash was observed in 2 
patients, for whom no biopsies were available [Bajetta et al, 1998]. Extreme 
progressive fatigue with severe deterioration of performance status was dose 
limiting for all patients treated at 1.25 ~g/kg. Fatigue was not described as dose 
limiting in other Phase I studies. It was however a consistent observation in 
murine and primate models [Bree et al, 1994; Coughlin et al, 1997]. 
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Furthermore, in an early terminated Phase II study, one third of patients suffered 
grade 3 to 4 fatigue [Leonard et al, 1997]. 
We observed a reduction of 55 to 80% of the mean AUC when repeated 
injections of IL-12 were compared with the initial injection at the same dose 
level. This was accompanied by reduction of side effects and resultant increase of 
the MTD. Motzer [Motzer et al, 1998] observed an AUC after up-titration dose 
escalation that was lower than the AUC of the first injection at the same dose. 
We could not attribute the decrease of the AUC with repeated injections to 
inhibited resorption or greater clearance from the peripheral blood of free IL-12, 
because T mox and T, did not change significantly. Neither did we observe the 
development of IL-12 antibodies. However, a possible explanation, which we 
have not investigated, would be that concentrations of soluble IL-12 receptors 
increase in the course of IL-12 treatment. IL-12 has been shown to upregulate 
its own receptors in peripheral blood CD56+ NK cells [Naume et al, 1993a]. Also, 
IL-12 enhances the expression of mRNA transcripts of one of the subunits of the 
IL-12 receptor in naive T-cells [Rogge et al, 1997]. For other cytokines, a 
negative feedback mechanism operates at persistent high cytokine levels, by the 
increased release of soluble cytokine receptor fragments that inhibit the effects 
of the cytokines. The eventual existence of such a mechanism in IL-12 requires 
additional research. 
Recently, it was shown in humans that the insertion of a treatment free 
period of a week after the first administration of IL-12 reduces the toxicity of 
subsequent injections [Leonard et al, 1997; Cohen, 1995]. In a study that used a 
dose of IL-12 that was previously well tolerated in a schedule that was identical 
except for the omission of a treatment free period after the first dose, severe 
toxicity and deaths occurred and necessitated early cessation of the study 
[Atkins et al, 1997; Leonard et al, 1997]. Subsequently it was shown in murine 
and primate models that a single injection of IL-12 before consecutive daily 
dosing protected the animals from toxicity and mortality and was accompanied 
by reduced IFN-y levels [Coughlin et al, 1997; Leonard et al, 1997; Sacco et al, 
1997]. Reduced IFN-y production seems an important feature of the down-
regulation of the toxic effects of ll-12 in the course of treatment [Sacco et al, 
1997]. Many of the side effects that accompany Il-12 therapy are considered to 
be IFNI' dependent because they are also encountered in studies with IFN-y 
[Quesada, 1995; Thompson et al, 1987]. In a pilot study of s.c. IL-12, 0.5 
J.Lg/kg/week, a decrease of IFN-y peak levels was demonstrated with subsequent 
injections [Bajetta et al, 1998]. Although Atkins et al report higher IFNI' peak 
levels during the first 5-day treatment course than after the initial dose, peak 
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levels thereafter declined during subsequent cycles [Atkins et al, 1997]. IL-10 
may be another cytokine that contributes to the counter regulation of the 
biological effects of IL-12. We have observed a decrease of IFN-y peak levels 
together with increased levels of IL-10 in the course of treatment [Portielje et al, 
2002a]. 
Our results raise the question whether the anti-tumor activity of IL-12 is 
downregulated in the course of treatment as well. An unfortunate correlation 
may exist between IL-12 induced toxicity and anti-tumor efficacy. 
Antibody neutralization of endogeneous IFN-y was shown to suppress 
antitumor effectiveness of IL-12 in murine models. Therefore, part of the anti-
tumor effects of IL-12 seems due to induction of IFN-y. However, exogeneous 
administration of IFN-y is not as effective as IL-12 [Nasta Ia et al, 1994; Fujiwara 
et al, 1996; Coughlin et al, 1995]. Additionally, it was shown in an animal model 
that giving a single dose of IL-12, a week prior to daily administration, did 
diminish IFN-y induction and toxic effects but left the anti-tumor activity largely 
unaffected [Coughlin et al, 1997]. 
In conclusion, the s.c. administration of rHuiL-12 as an initial injection at a 
dose of 0.5 ~g/kg, followed after a week rest by repeated injections at a dose of 
1.0 ~g/kg, 3 times a week, was well tolerated. A decrease of toxicities and a 
reduction in the AUC of IL-12 was observed with repeated injections. 

Chapter 3 
Repeated administrations of IL-12 are associated with 
persistently elevated plasma levels of IL-10 and declining 
IFN-y, TNF-a, Il-6 and IL-8 responses 
Adapted from: 
Repeated administrations of IL-12 are associated with persistently elevated 
serum levels of IL-10 and declining IFN-y, TN F-a, IL-6 and IL-8 responses 
Johanna E. A. Portielje, Cor H. J. Lamers, Wim H. J. Kruit, Alex Sparreboom, 
Reinder L. H. Bolhuis, Gerrit Stoter, Christoph Huber, and Jan-Willem Gratama 
Clinical Cancer Research, in press 
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Abstract 
Repeated administrations of recombinant human IL-12 (rHuiL-12) to cancer 
patients is characterized by a reduction of side effects during treatment. 
Induction of IFN-y, considered a key mediator of anti-tumor effects of IL-12, is 
known to decline upon repeated administrations. We studied whether other 
immunological effects of rHulL-12 are tapered in the course of treatment. 
In a phase I study of 26 patients with advanced renal cell cancer, rHulL-12 
was administered s.c. on day 1, followed by 7 days rest and 6 injections 
administered over a 2-week time period. Plasma concentrations of various 
cytokines were monitored, as well as absolute counts of circulating leukocyte and 
lymphocyte subsets. 
The first injection of IL-12 was accompanied by rapid, transient and dose 
dependent increments of plasma levels IFN-y, TNF-a, IL-10, IL-6, IL-8, but not 
IL-4, as well as rapid, transient and dose dependent reductions of lymphocyte, 
monocyte and neutrophil counts. The major lymphocyte subsets, i.e., CD4+ and 
CDS+ T cells, 6 cells and NK cells, followed this pattern. Upon repeated rHuiL-12 
injections, IL-10 concentrations increased further, whilst the transient 
increments of IFN-y, TNF-a, IL-6 and IL-8 concentrations, as well as the 
fluctuations of the leukocyte subset counts were tapered. Dose escalation of IL-
12 within clinically tolerable margins did not reduce the decline of these 
immunological effects. 
Conclusion: Induction of pro-inflammatory cytokines and associated 
fluctuations in leucocyte subset counts decrease upon repeated administrations 
of rHuiL-12. The steady increment of IL-10 plasma levels may mediate the 
observed down-regulation of clinical and immunological effects. 
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Introduction 
Interleukin 12 (IL-12) is a cytokine with an important function in the 
regulation of the cell-mediated immune response. In animal and in vitro models, 
IL-12 stimulates CD4+ Th-1 responses and promotes the proliferation and 
activation of natural killer (NK) cells and stimulates them to produce interferon-
gamma (IFN-y) [Trinchieri, 1995]. IL-12 also stimulates antigen specific CDS+ T 
cell responses [Mortarini et al, 2000; Curtsinger et al, 1999]. Additionally, IL-12 
has anti-angiogenic properties [Gee et al, 1999] and a direct growth inhibitory 
effect on tumor cells [Su et al, 2001]. The promising anti-tumor effects that were 
observed in murine and non-human primate models [Brunda et al, 1993] 
prompted clinical studies in patients with cancer. Efficacy studies of recombinant 
human IL-12 (rHuiL-12) have now been performed in patients with ovarian 
cancer and renal cell cancer, but anti-tumor responses have been disappointing 
[Motzer et al, 2001; Hurteau et al, 2001]. During Phase I testing of recombinant 
human IL-12, we and others have observed a decrease of side effects upon 
repeated administrations in conjunction with a reduction of IFN-')' release 
[Portielje et al, 1999; Coughlin et al, 1997; Leonard et al, 1997; Sacco et al, 
1997;]. Because IFN-y is considered to be a key mediator of anti-tumor effects of 
IL-12 [Fujiwara et al; 1997], the down-regulation of IFN-y release observed upon 
repeated IL-12 administrations may be related to the lack of anti-tumor effects 
of IL-12. 
Here we assessed whether or not the down-regulation of IFN-y production 
that occurs upon repeated rHuiL-12 administrations: (a) comprised other 
immunological effects, (b) was accompanied by up-regulation of an inhibitory 
immune regulatory mechanism or cytokine, and (c) could be prevented by dose 
escalation of rHuiL-12. To this end, we studied the in vivo effects of rHuiL-12 in 
26 patients with advanced renal cell cancer, treated in a phase I study [Portielje 
et al, 1999]. We studied: (a) plasma levels of cytokines: IFN-y, TNF-o:, IL-10, IL-
S, IL-6 and IL-4; (b) absolute numbers of circulating neutrophils, lymphocytes 
and monocytes, and (c) the major lymphocyte subsets: CD4+ and CDS+ T cells, 
B cells and NK cells. We compared the effects of the first rHulL-12 dose with 
effects of subsequent repeated administrations at the same or escalated doses. 
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Patients and Methods 
Study design 
We studied 26 patients with locally advanced or metastatic renal cell cancer 
who participated in an open-label, non-randomized phase I dose escalation trial. 
This trial was carried out in the Rotterdam and Mainz cancer centers to evaluate 
the safety and tolerability of an initial single s.c. injection of rHuiL-12, followed 
by repeated injections. Patients had a median age of 56 years (range 41 to 70 
years). They had not received more than one previous immunotherapeutic 
intervention and all former therapies were terminated at least 6 weeks prior to 
start of treatment with rHulL-12. Inclusion criteria were a World Health 
Organization (WHO) performance score of 0 or 1 and adequate hematological, 
renal, hepatic, cardiovascular and pulmonary functions. None of the patients 
received systemic corticosteroid therapy. All patients had given written informed 
consent. 
RHuiL-12 (Ro 24-7472) was supplied by Hoffmann-La Roche (Nutley, N.J.) 
and administered by s.c. injections. On day 1 a single injection of rHuiL-12 was 
given, followed by an observation period of 7 days. Subsequently, on day 8, a 2-
week cycle was started, with 3 injections per week. Immuno-modulatory effects 
of the first administration of rHu!L-12 were studied in 26 patients after a dose of 
0.1 ~g/kg (n~3), 0.5 ~g/kg (n=19) or 1.0 ~g/kg (n~4). The immunological 
effects of repeated injections were studied in 18 patients who received all 7 
injections each. Twelve of these patients received the same dose of rHuiL-12 for 
the initial as well as the repeated injections: 0.1 ~g/kg (n=3), 0.5 ~g/kg (n~7) or 
1.0 ~g/kg (n~2). The remaining 6 patients started with an initial dose of 0.5 
~g/kg rHuiL-12 and repeated injections were administered at a dose of 1.0 ~g/kg 
(n=4) or 1.25 ~g/kg (n=2). 
Cytokines 
EDTA-anticoagulated venous blood samples for measurement of cytokines 
were obtained directly before and 4, 8, 12, 24, 48 and 72 hours after the first 
and seventh administration of rHuiL-12. In 12 patients blood was also obtained 
96 and 168 hours after the first injection. Plasma was obtained after 
centrifugation of blood for 10 minutes at 1300g. Plasma samples were stored at 
-70°C until tested. Serum concentrations of bio-active IL-12 were measured by a 
method of antibody capture followed by a cell proliferation assay with a lower 
limit of detection of 50 pg/ml [Motzer et al, 1998]. IFN-y, TN F-a, IL-10, IL-8, and 
IL-6 concentrations were determined with commercially available enzyme 
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amplified sensitivity immunoassays (Medgenix EASIA, Biosource Europe, Fleurus, 
Belgium). The lower limits of detection of the assays were: IFN""')': 0.03 IU/ml; 
TNF-a: 3 pg(ml; IL-10: 1 pg(ml; IL-S: 1 pg(ml; IL-6: 2 pg/ml and IL-4: 0.2 
pg/ml. 
Determination of absolute numbers of peripheral-blood leukocyte subsets 
Blood samples for determination of absolute numbers of peripheral blood 
leukocyte subsets were obtained from 22 patients after an initial dose of 0.1 
)lg/kg (n~3), 0.5 Jlg/kg (n~15) or 1.0 )lg/kg (n~4). Samples were obtained 
directly before and 1, 2, 3, 4 and 7 days after the first administration of rHu!L-
12, before every subsequent administration, and 7 days after the last 
administration. Leukocyte concentrations and differential counts were 
determined in EDTA anticoagulated blood samples using a Technicon H1 
automated cell counter (Technicon, Tarrytown, NY). 
Lymphocyte Immunophenotyping 
Immunophenotyping was performed on blood specimens from 9 patients. All 
patients studied received an initial injection of 0.5 )lg/kg rHulL-12. The repeated 
injections were dosed at 0.5 )lg/kg (n~4), 1.0 Jl9/kg (n~3) or 1.25 )lg/kg (n~2). 
Heparinized venous blood samples for immunophenotyping were obtained 
directly before (day 0) and one day after the first administration (day 1), and 
directly before (day 19) and one week after (day 26) the last administration of 
rHu!L-12. For immunostaining the erythrocytes were lysed by ammonium-
chloride. The remaining leukocytes were washed and stained using the following 
mixtures of monoclonal antibodies (mAb) conjugated either with fluorescein 
isothiocyanate (FITC) or phycoerythrin (PE): CD45 FITC + CD14 PE; CD3 FITC + 
CD16 PE + CD56 PE; CD3 FITC + CD4 PE; CD3 me + CDS PE; CD19 PE. 
Isotype control mAb (mouse IgG2, FITC, mouse IgG1 me and mouse IgG1 PE) 
were used to visualize non-specific antibody binding. The CDS PE mAb was 
obtained from DAKO (Giostrup, Denmark). All other mAbs were purchased from 
BD Biosciences (San Jose, CA). Sample processing and flow cytometry were 
performed as described elsewhere [Gratama et al, 1996]. 
Statistical analyses 
To test differences for any parameter between paired samples, for statistical 
significance, two-tailed paired Student's t-tests were performed. To test 
differences for any parameter between non-paired samples, two-tailed non-
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paired Student's t-tests were performed. P values <0.05 were considered 
statistically significant. 
Results 
Cytokines 
The first administration of rHull-12 was followed by increments in plasma 
concentrations of IFN-y, TNF-a, IL-6, IL-8 and IL-10, whereas virtually no 
elevation of IL-4 concentrations was observed (Figure 1). Table 1 shows the 
baseline and peak levels of cytokines as measured in individual patients during 7 
days following the first rHull-12 injection, stratified by rHuiL-12 dose level. The 
pharmacokinetics of rHuiL-12 in this study has been reported previously 
[Portielje et al, 1999]. Samples from 25 patients were available for IL-12 
assessments. 
After 0.5 ~g/kg rHuiL-12, increments of plasma IL-12 were observed in 10 
out of 18 patients and after 1.0 ~g/kg rHuiL-12, increments were observed in all 
four patients. At the lowest dose, i.e. 0.1 ~g/kg rHull-12, plasma concentrations 
of !L-12 remained undetectable in all 3 patients. After 0.5 ~g/kg, IL-12 became 
detectable in 10 of 18 patients and after 1.0 ~g/kg, ll-12 became detectable in 
all 4 patients. 
The initial induction of IFN-y, TN F-a, ll-6, IL-8 and ll-10 occurred in a rHull-
12 dose-dependent way. Following administration of the lowest dose, i.e. 0.1 
~g/kg, only a significant increment of TN F-a plasma levels was observed. Upon 
administration of 0.5 ~g/kg, peak levels of !FN-y, TNF-a, !L-6, IL-8 and ll-10 
were significantly higher than the corresponding levels prior to therapy. At the 
highest rHull-12 dose level, i.e. 1.0 ~g/kg, peak levels of IFN-y, TN F-a, IL-8 and 
IL-10 were even higher than those observed after administration of 0.5 ~g/kg. Of 
note, no increments of IL -4 plasma levels were observed at the 0.1 and 0.5 
~g/kg dose levels, whilst these became just detectable within 24 h after 
administration of 1.0 ~g/kg rHuiL-12. 
The first rHuil-12 injection resulted in increments of plasma concentrations 
of IFN-y and TNF-a in all patients, whereas increments of IL-10 were 
demonstrated at the 0.1 ~g/kg dose level in 1 of 3 patients (33%), at the 0.5 
~g/kg dose level in 11 out of 19 patients (58%), and at the 1.0 ~g/kg dose level 
in all 4 patients (100%). The first rHu!L-12 injection resulted in increments of IL-
8 in all but 5 patients, 3 of whom already had elevated baseline levels of IL-8 
(between 26 and 58 pg/ml). 
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Figure 1. Plasma concentrations of IFN-y, IL-10, TN F-a, n.-8, Il-6, Il-4 and n.-
12 after the first s.c. injection of IL-12. 
Median plasma concentrations of IFN-,; IL-10, TNF-a, IL-8, IL-6 and IL-4 
during a period of seven days after the first s.c. administration of 0.1 pgjkg 
rHuiL-12 (•, 3 patients), 0.5 pg/kg (0, 19 patients) or 1.0 pg/kg (A, 4 
patients). Dotted lines indicate the upper limit of the normal range. 
Table 1. Baseline and maximum cytokine concentrations after the first subcutaneous administration of rHuiL-12 
0.1J19/kg o.s 1,9;k9 1.0 pgjkg 
(n=3) (n=19) (n=4) 
Baseline Maximum Baseline Maximum Baseline Maximum 
Median Range Median Range Median Range Median Range Median Range Median Range 
IL-12 (pg/ml) <50 <50 <50" 298 ** 116- 830 <50 548 475-2630 
IFN-y {IU/ml) <0.03 <0.03- 0.4 2.6° 1.4- 2.9 <0.03 <0.03 - 1.4 13 .. 1.5 - 41 0.4 <0.03- 0.5 55 12 - 184 
IL-10(pg/ml) <1 # 15 <1' <1 - 6 22 ** 4- 49 <1 37. 27- 81 
TNF-cx(pg/ml) 26 21-40 84' 73 - 108 25 8- 83 95 n 60 - 143 25 7- 33 168' 149 - 223 
IL-8 (pg/ml) 5 <1 - 15 24 11 -53 11' <1 - 35 38' 14 - 223 < 1 <1 - 8 53' 32- 87 
IL-6 (pg/ml) 6' <2- 10 25 22- 27 16 ' <2- 79 82 ** 17 - 280 <2 83 * 42 - 137 
* = p< 0.05, ** = p<0.001; Paired comparison between maximum levels and baseline levels. 
As described in the results, induction of the various cytokines did not occur in all patients. In this table only data from patients with 
Increments of cytokine concentrations post IL-12 are shown. Symbols denote the numbers of patients in which Increments of 
cytokine plasma levels have been observed: # n=1; § n= 14; £ n=13; ¥ n=2; * n=16; ~ n=10. 
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Increments of IL-6 levels were observed in all but 4 patients, 1 of whom 
already had a strongly elevated base-line level of 91 pg/ml. IL-6 plasma 
concentrations were the first to peak at a median of 12 hours post injection 
(range 8-72 hours in individual patients), followed at 24 hours by IFN-y (range 
12-72 hours) and at 48 hours by TNF-a (range 24-72 hours), IL-10 (range 8-72 
hours) and IL-8 (range 8-168 hours) (Figure 1). 
Thereafter, levels of TNF-a, IFN-y, IL-10, IL-8 and IL-6 gradually declined. 
IFN-y and IL-10 became undetectable at 7 days after rHu!L-12 injection, whilst 
TN F-a, IL-6 and IL-8 remained detectable around the upper limits of their normal 
ranges. 
Comparison of the effects of the first and seventh injection of rHuiL-12 on 
cytokine plasma levels revealed that IL-10 still showed a significant increment 
after 7 injections at the same dose level (i.e., 0.5 ~g/kg; Figure 2, Panels A and 
B). In contrast, IFN-y showed only a marginally significant increment after the 
seventh rHuiL-12 injection (Panels G and H), whilst TN F-a (Panels D and E), IL-8 
and IL-6 (data not shown) showed hardly any increments as compared with the 
corresponding increments after the first injection of the same dose of rHuiL-12. 
The reduced increments of plasma levels of these cytokines were not only 
observed at the 0.5 ~g/kg dose level, but also at the 0.1 and 1.0 ~g/kg dose 
levels (results not shown). 
The effect of IL-12 dose escalation was further studied in 6 patients who 
received, after the initial injection of 0.5 ~g/kg rHuiL-12, subsequent injections 
at doses of 1.0 or 1.25 ~g/kg rHuiL-12. These dose escalations resulted in an 
even stronger increment of IL-10 plasma levels as compared to the 0.5 ~g/kg 
dose level (Figure 2, Panels A to C). However, increments of IFN-y (Panels G to 
I), TN F-a (Panels D to F), IL-6 and IL-8 plasma levels (data not shown) remained 
clearly less after the seventh than after the first rHu!L-12 injection. 
Leukocyte subsets 
The administration of rHuiL-12 was followed by a rapid and transient 
decrease of absolute numbers of lymphocytes, monocytes and neutrophils in the 
peripheral blood (figure 3). Table 2 shows the baseline values and nadirs of these 
cell counts after the first injection of rHuiL-12. The reduction of lymphocytes, 
monocytes and neutrophils occurred in a rHuiL-12 dose dependent way. The 
lymphocytes reached their nadir at 1 to 2 days after rHu!L-12 administration, 
followed by the monocytes at 2 to 3 days, and the neutrophils at 3 to 4 days. At 
the 0.1 ~g/kg dose level, all leucocyte subsets had returned to their baseline 
levels within 7 days. 
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Figure 2. Cytoklne concentrations after the first injection of IL-12 (A), compared to concentrations after the seventh 
injection at the same (B), or escalated dose of IL-12 (C). Median plasma concentrations of IL-10, TNF-a and IFN-y 
were measured during a period of 7 days after the first and after the seventh administration of rHuiL-12. 13 Patients 
received a first s.c. injection of 0,5 pg/kg (panels A, D and G), Subsequently, 7 of them received, starting on day 8, repeated 
administrations at the same dose level (panels B, E and H) and 6 of them received subsequent administrations at dose levels 
1.0 or 1.25 pg/kg rHuiL-12 (panel C, F and I). Significant differences between concentrations before and after IL-12 injection 
are Indicated by an asterlx (p< 0.05, paired samples). Dotted lines Indicate the upper limit of the normal range. 
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Figure 3. leukocyte sub-populations after repeated administrations of IL-12. 
Absolute numbers of lymphocytes, monocytes and neutrophils in the 
peripheral blood during 26-days following the first rHuiL-12 injection. Arrows 
depict rHuiL-12 administrations. Patients were treated with multiple doses of 
0.1 pg/kg (~: 3 patients), 0.5 pg/kg (0: 7 patients) or 1.0 pgjkg rHuiL-12 
(A: 2 patients). For each time point, the median result of each dose group is 
shown. Dotted lines indicate the lower and upper limits of the normal range. 
Table 2. Leukocyte subsets after the first subcutaneous administration of rHuiL-12 
O.lpg/kg 0.5pg/kg 
(n=3) (n=15) 
Baseline"' Nadir"' Baseline'¥ 
cell count cell count 
Median Range Median Range Median Range 
Lymphocytes 1.8 1.5- 1.9 0.8 .. 0.5 - 0.8 1.3 0.5- 2.9 
Neutrophlls 4.0 3.5-4.1 0.9 4.2 2.7 - 6.8 
Monocytes 0.53 0.46 - 0.66 0.21 0.17-0.38 0.30 0.17- 0.58 
* = p< 0.05; ** = p<0.001; nadirs compared to paired baseline counts. 
'I' Absolute numbers shown are x 109 I L 
Nadir'~' 
Median Range 
o.s·· 0.1 - 1.1 
1.5 .. 0.7- 4.7 
0.15" 0.03- 0.43 
1.0 pg/kg 
(n=4) 
Basellne9 Nadir"' 
cell count 
Median Range Median Range 
1.4 1.0 - 2.3 0.3· 0.2 - 0.5 
3.7 2.9 - 5.3 1.4' 1.1- 1.7 
0.35 0.29- 0.5 0.11' 0.02-0.16 
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However, at the 0.5 and 1.0 !19/kg dose levels, neutrophils were still below 
baseline in 18 of 19 patients at 7 days post injection, whilst monocytes and 
lymphocytes were still below baseline levels in 10 out of 19 patients at that time 
(data not shown). 
Repeated injections of rHuiL-12 had only minor effects on the numbers of 
circulating leucocyte subsets as compared to the first injection. 
The subsequent injections at the 0.1 !19/kg dose level had no significant 
effects. At the 0.5 and 1.0 !J.g/kg dose levels, neutrophil counts were still below 
baseline levels, yet within normal ranges at 48 h after the 6th rHuiL-12 injection. 
However, at the highest dose levels, i.e. 1.0 and 1.25 !J.g/kg, a marked 
lymphopenia persisted during the entire period of follow-up (data not shown). 
CD3-, 16+ and/or 56+ NK lymphocytes CD19+ B lymphocytes 
= = 
,00 1 HllH ,., 1 HllH 
'~ '~ 
• . 
A-----
,00 . . . '"0 • ~ • 
' 
. 
. 
" • 
. 
. 
. 
" 
...__- --------- .... --
"E ' . . ~ g 0 0 0 
" " " " " 
0 
'" " "' " " • ~ 
0 
0 CD3+ ,4+ T lymphocytes CD3+,8+ T lymphocytes 
"" ~
E 
~ '000 '~ ~ 
'" 1 HllH '" 1 HllH 
• • 
"" 
___ .... ____ 
"" 
"" "" 
__ ... ----+ 
.. 
'* ---...
0 0 
0 
" " "' " " 
4 
'" " "' " " 
Time (days) 
Figure 4. lymphocyte sub-populations after repeated administrations of Il-12. 
Absolute numbers of natural killer cells (CD3-,16+ and/or 56+), 8-/ymphocytes 
(CD19+), T-he/per cells (CD3+,4+) and cytotoxic T-ee/Is (CD3+,8+) during 
26-days following the first rHuiL-12 injection. Arrows depict rHuiL-12 
administrations. Patients either received a first injection of 0.5 pg/kg and 
subsequent injections either at the same dose level {n=4) or higher dose level 
(1.0 pg/kg (n=3); 1.25 pg/kg (n=2)). For each time point, the median result 
is shown. Dotted lines indicate the lower and (for CD3+, 8+ T cells) upper 
limits of the normal range. Significant differences between base-line cefl 
counts and cell counts after IL-12 injection are indicated by an asterix (p< 
0.05, paired samples). 
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Lymphocyte subsets 
Figure 4 shows the absolute numbers of NK lymphocytes (CD3-, 16+ and/or 
56+), B lymphocytes (CD19+), T-helper cells (CD3+, 4+) and cytotoxic T cells 
(CD3+, 8+) before and after treatment with rl-luil-12. 
Prior to treatment, all lymphocyte subsets were in the normal range. The first 
administration of 0.5 ~g/kg rHuil-12 induced significant reductions of all 
lymphocyte subset counts to levels below their normal ranges. 
At 24 h after rHuil-12 injection, NK cells had decreased from a median of 
123 (range 38-314) to 16 (3-42) cells per mm3 B cells from a median of 90 
(range 21-240) to 36 (3-178) cells per mm3 T-helper cells from a median of 569 
(range 66-1262) to 219 (22-637) cells per mm3 and cytotoxic T cells from a 
median of 193 (range 240-854) to 59 (8-261) cells per mm3 Immediately before 
and 7 days after the last injection of rHuiL-12, NK and cytotoxic T cells had 
returned to their baseline levels, whereas T-helper cell and, in particular, B-cell 
counts were still below these levels. 
Discussion 
Clinical side effects and IFN-y induction decrease in the course of repeated 
IL-12 administrations to humans [Portielje et al, 1999; Leonard et al, 1997; 
Robertson et al, 1999; Bajetta et al, 1998; Rakhit et al, 1999; Haicheur et al, 
2000; Gollob et al, 2000]. Here, we show that other immunological effects of Il-
12 are also down-regulated in the course of systemic Il-12 treatment, such as 
declining TNF-o:, IL-8 and IL-6 responses and diminishing effects on leucocyte 
subsets, and that maintenance of detectable concentrations of IFN-y, as well as 
TNF-a, IL-8 and Il-6, can not be achieved by dose escalation of Il-12. A 
previous phase I study has shown an association between antitumor response 
and the maintenance of IFN-y concentrations after repeated injections [Gollob et 
al, 2000]. These combined results indicate that a generalized down-regulation of 
immunological effects, possibly including anti-tumor effects, occurs upon 
repeated administrations of ll-12. 
We showed that the plasma levels of the inhibitory cytokine Il-10 remained 
elevated or further increased upon repeated ll-12 injections. This observation 
has also been made in other clinical trials [Bajetta et al, 1998; Haicheur et al, 
2000; Zeuzem et al, 2000]. An important role has been proposed for IL-10 in the 
down-regulation of IFN-y production, as anti-IL-10 antibodies neutralized the 
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down-regulation of side effects upon repeated Il-12 administrations to mice, and 
Il-10 inhibited Il-12-mediated production of IFN-y by human lymphoid cells 
[Sacco et al, 1997; Bajetta et al, 1998; Haicheur et al, 2000; D'Andrea et al, 
1993; Pai et al, 1998]. Based on our results we suggest that Il-10 down-
regulates the Il-12-mediated production of other cytokines as well. Indeed, in 
vitro studies have shown that Il-10 inhibits TNF-a production by lymphocytes 
[D'Andrea et al, 1993], Il-6 and IL-8 production by monocytes and macro phages 
[Fiorentino et al, 1991; Hodge-Dufour et al, 1998], and IL-8 production by 
neutrophils [Wang et al, 1994]. In various pathological states, endogenously 
produced IL-10 has an important function in the abrogation of ongoing 
inflammatory responses by inhibiting the effects mediated by endogenously 
produced IL-12 [Meyaard et al, 1996; Van der Poll et al, 1997; De Waal Malefyt 
et al, 1991; Jansen et al, 1996]. Hence, IL-12-induced IL-10 production appears 
to be a protective feedback mechanism. The induction of IL-10 seems to be 
independent of IFN-y as neutralizing anti-IFN-y antibodies had no effect on IL-12 
induced IL-10 synthesis in vitro [Windhagen et al, 1996]. On the other hand, 
TNF-a possibly plays a role in the increased Il-10 production after IL-12 
administration, as it induced high levels of Il-10 mRNA expression and release of 
IL-10 by human peripheral blood monocytes [Wanidworanun et al, 1993]. 
Moreover, TNF-a was shown to inhibit IFN-y-mediated effects on human 
macrophages, and the inhibition of these effects by anti-Il-10 antibodies 
confirmed the intermediate role of Il-10 [Hodge-Dufour et al, 1998]. 
IL-18 is a pleiotropic cytokine that initially was discovered as IFN-y inducing 
factor derived from liver cells [Okamura et al, 1995]. IL-18 synergizes with Il-12 
to stimulate IFN-y production by T cells [Mikallef et al, 1996]. In a phase I study 
of Il-12 to cancer patients, induction of Il-18 and IFN-y were not correlated; 
upon repeated IL-12 administrations, IL-18 induction was sustained, whilst IFN-y 
induction was downregulated [Gollob et al, 2000]. In addition, IL-18 plasma 
levels peaked later than those of IFN-y [Gollob et al, 2000]. Extrapolation of 
these observations to our results would therefore suggest that the kinetics of 
IFN-y plasma levels in our study are independent of IL-18. 
Finally, the downregulation of IL-12-mediated effects upon repeated IL-12 
administration may be due to the specific downregulation of its own signaling 
[Wang et al, 2001]. In vitro, prolonged stimulation ofT cells by IL-12 results in 
depletion of the signal transducer and activator of transcription 4 (STAT4) 
protein. Downregulation of STAT4, a critical IL-12 signaling component, resulted 
in decreased IFN-y production [Wang et al, 2001]. In line with these findings, we 
observed a generalized reduction of biological effects in vivo upon repeated 
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adminstration of IL-12 at doses approximating the maximum tolerated dose 
[Portielje et al, 1999]. 
We have shown that the administration of IL-12 to humans resulted in the 
release of TN F-a, IL-8 and IL-6, in addition to that of IFN-y and IL-10. The dose-
dependent induction of multiple cytokines after the first injection of ll-12 is 
probably a combination of direct and indirect IL-12 mediated effects. Activated T 
and NK cells and, as shown recently, neutrophils, eosinophils and dendritic cells 
[Desai et al, 1992; Collison et al, 1998; Nutku et al, 2001, Nagayama et al, 
2000] express ll-12 receptors and IL-12 potentially mediates the production of 
secondary cytokines by binding to these cell populations. With respect to TN F-a, 
our results are in accordance with previous reports of elevated plasma TNF-a 
concentrations and increased TNF-a mRNA expression in peripheral blood 
mononuclear cells of patients with advanced cancer treated with IL-12 [Ohno et 
al, 2000; Haicheur et al, 2000]. In vitro, IL-12 stimulates the production of TN F-
a by activated T cells and NK cells [Naume et al, 1992; Aste-Amezaga et al, 
1994]. As monoclonal antibodies to TNF-a abrogate IL-12 mediated IFN-y 
production in response to various stimuli in-vitro [D'Andrea et al, 1993; Tripp et 
al, 1993], TNF-a may be an essential co-stimulator of IFN-y production and 
therefore an important intermediate in the anti-tumor effects of IL-12. 
One study has addressed the issue of IL-8 concentrations after IL-12 in 
humans and described inconsistent patterns of stimulation [Bajetta et al, 1998]. 
In contrast, we observed induction of IL-8 in the vast majority of patients. TN F-a 
is a physiological stimulant of IL-8 production in humans [Van der Poll et al, 
1992], and therefore, the induction of IL-8 may be secondary to TN F-a induction 
by rHuiL-12 in our study. Cells from the monocyte and macrophage 
compartment, endothelial cells and neutrophils are among the cells that can be 
stimulated by TN F-a to produce ll-8 [Baggiolini et al, 2000; Ethuin et al, 2001]. 
Alternatively, IL-8 induction may be a direct effect of rHuiL-12, as this cytokine 
was shown to induce the production of IL-8 from purified NK-cells [Naume et al, 
1993b]. 
We also demonstrated that IL-6 peaks within 12 hours after s.c. IL-12 
administration. Previous studies that addressed IL-6 reported large variation of 
plasma concentrations among patients and lack of IL-12 dose dependency 
[Bajetta et al, 1998; Ohno et al, 2000]. IL-6 peak levels may have been missed 
in these studies as the the first blood samples were not taken until 24 hours after 
ll-12 administration. Although TNF-a can stimulate IL-6 induction in humans 
[Van Snick, 1990], it probably had no major impact on IL-6 production in our 
patients, since IL-6 already reached peak levels 36 hours before TNF-a. Rather, 
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stimulation of IL-6 production may be directly mediated by IL-12, as binding of 
IL-12 to its receptors on dendritic cells has been shown to stimulate the 
production of IFN-y, TNF-a and IL-6 at the transcription level [Nagayama et al, 
2000]. IL-6 may also be considered as a natural feedback inhibitor of IL-12 
production, as IL-6 inhibits both T-cell dependent and independent induction of 
IL-12 production in humans [Takenaka et al, 1997]. 
The transient reduction of lymphocyte, monocyte and neutrophil counts 
following the first IL-12 injection confirms previous observations [Robertson et 
al, 1999; Bajetta et al, 1998; Atkins et al, 1997]. We consider this pattern to 
reflect the transient redistribution of leukocytes, which adhere to endothelium 
and migrate into the tissues. Indeed, postmortem examination of animals treated 
with IL-12 showed massive infiltrates of leucocytes in lymph nodes, lungs, liver 
and spleen [Car et al, 1999]. The accumulation of NK and T cells in tumor 
nodules after IL-12 administration seems relevant to explain the putative anti-
tumor effects of IL-12 [Mortarini et al, 2000; Allavena et al, 1994; Fogler et al, 
1998]. Although in-vitro studies have demonstrated that IL-12 directly promotes 
interactions between endothelial cells and T cells, NK cells and neutrophils 
[AIIavena et al, 1994; Colantonio et al, 1999], secondary cytokines such as IFN-
y, TNF-a and IL-8 may also contribute to the redistribution of leukocytes, as 
these cytokines enhance the expression of a wide range of molecules that 
regulate leukocyte adhesion and migration [Male, 1995]. In addition, chemokines 
induced by IFN-y, such as IFN-y-inducible protein 10 (IP-10) and monokine 
induced by IFN-y (MIG) have potent chemotactic effects on T cells and may have 
contributed to their distribution [Haicheur et al, 2000]. As with IFN-y, induction 
of these chemokines declines upon repeated IL-12 administrations [Haicheur et 
al, 2000]. 
In patients with advanced melanoma treated with s.c. IL-12, serum levels of 
the soluble endothelial adhesion molecules E-selectin, vascular cell adhesion 
molecule (VCAM)-1 and intercellular adhesion molecule (ICAM)-1 were 
transiently increased after IL-12 administration [Mortarini et al, 2000]. In 
parallel, the expression of their respective ligands, i.e., cutaneous lymphocyte 
antigen (CLA), very late antigen (VLA)-4 and lymphocyte function associated 
antigen (LFA)-1, were increased on circulating T cells. Thus, the enhanced 
expression of both receptors and ligands on endothelial cells and T lymphocytes 
may have promoted the marked infiltration of the melanoma lesions by tumor-
specific CDS+ T cells observed in this study [Mortarini et al, 2000]. 
The development of IL-12 as a cancer therapeutic has followed the classical 
approach, starting with phase I studies, followed by efficacy studies with the 
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maximum tolerated dose that was previously defined. Our results indicate that 
the disappointing anti-tumor effects observed in phase II studies are possibly 
due to a generalized reduction of biological effects that occurs when Il-12 is 
repeatedly administered at doses and in schedules that approximate the 
maximum tolerated dose. 
We conclude that the systemic administration of Il-12 results in direct and 
indirect induction of multiple cytokines. Upon repeated Il-12 administration, 
levels of pro-inflammatory cytokines diminish as well as effects on peripheral 
blood leucocyte subsets, while Il-10 production increases and likely contributes 
to the down-regulation. Dose escalation of ll-12, within tolerable margins, does 
not prevent the down-regulation of immunological effects. At present, Il-12 is 
being studied as an adjuvant for cancer vaccination. The present study indicates 
that the effects of ll-12 are down regulated when it is administered at dose levels 
near the maximum tolerated dose. Therefore, further investigations are required 
to define the dose and schedule of ll-12 with optimal immunological effects in 
the vaccination setting. 
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Interleukin 12 induces activation of fibrinolysis and 
coagulation in humans 
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Abstract 
Interleukin 12 has potential efficacy in malignant, infectious and allergic 
diseases. Its side-effects include activation of coagulation and fibrinolysis as 
documented in chimpanzees. We assessed the coagulative and fibrinolytic 
response in 18 patients with renal cell carcinoma after subcutaneous injection of 
0.5 !19/kg recombinant human IL-12. 
Il-12 induced a fibrinolytic response in 17 patients (94%): Plasmin-a2-
antiplasmin complexes (PAPc) increased from 11.8 ± 6.6 nmol/1 (mean± SD) to a 
maximum of 18.8 ± 7.4 nmol/1 at 72 hours. Baseline levels of tissue plasminogen 
activator (tPA) and plasminogen-activator inhibitor-I (PAl) were elevated in eight 
and 14 patients, respectively. tPA Increased from 12.6 ± 5.2 ng/ml to a 
maximum of 19.0 ± 6.7 ng/ml at 72 hours. PAI decreased from 111 ± 69 ng/ml 
to a minimum of 65 ± 53 ng/ml at 8 hours, thereafter remaining below baseline. 
Elevation of PAPc correlated with elevation of tPA and reduction of PAI. 
A coagulative response occurred in nine patients (50%): Thrombin-anti-thrombin 
III complexes increased from 29 ± 53 ng/ml to a maximum of 460 ± 322 ng/ml 
at 12 hours. Patients with and without a coagulative response had similar levels 
of rHull-12, IFN-y or TN F-a. 
Conclusion: IL-12 can activate both fibrinolysis and coagulation in a 
significant proportion of patients with cancer. The time-frame and sequence of 
these activation processes differ from those known for other cytokines. 
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Introduction 
Interleukin 12 (IL-12) is a cytokine with an important function in the 
regulation of the cell-mediated immune response. It stimulates the cellular 
immunity by promoting T-helper 1 responses while inhibiting T-helper 2 deve-
lopment and function and, therefore, may be used to restore dysbalances 
between Th-1 and Th-2 cells as may occur in malignant, infectious or allergic 
diseases [Manetti et al, 1993; Wu et al, 1993; Scott et al, 1993]. Additionally, 
IL-12 can inhibit tumor-associated angiogenesis [Voest et al, 1995; Sgadari et al, 
1996; Coughlin et al, 1998]. In animal models it was demonstrated that IL-12 
affects coagulation and fibrinolysis [Ozmen et al, 1994; Lauw et al, 1999]. In 
mice, IL-12 is an important mediator of the generalized Shwartzman reaction, a 
systemic inflammation with widespread thrombosis and disseminated 
intravascular coagulation [Ozmen et al, 1994]. Several cases of disseminated 
intravascular coagulation were observed after the administration of 5 ~g/kg IL-12 
to chimpanzees with viral hepatitis (personal communication T. Man, Roche). In 
healthy chimpanzees, the intravenous administration of 1 ~g/kg IL-12 induced 
activation of coagulation and fibrinolysis [Lauw et al, 1999]. Whether the 
administration of IL-12 in humans is also associated with changes in coagulation 
or fibrinolysis is unknown. 
An important immune-regulatory effect of IL-12 is the production of IFN"""f by 
T-lymphocytes and natural killer cells and many of the biological effects of IL-12 
therapy in humans are attributed to the induction of this cytokine [Kobayashi et 
al, 1989; Chan et al, 1991]. IFN"""f, in turn, stimulates monocytes and 
macrophages to secrete tumor necrosis factor-alfa (TN F-a) that has been shown 
to activate the common pathway of coagulation in humans [Van der Poll et al, 
1990]. 
To evaluate the involvement of IL-12 on coagulation and fibrinolysis, 
markers of coagulation and fibrinolysis were studied in patients with advanced 
renal cell carcinoma (RCC), treated in a phase I study with subcutaneous 
recombinant human IL-12 (rHuiL-12) at the maximum tolerated dose. 
Additionally, the pharmacokinetics of rHuiL-12 were studied and levels of IFN"""f 
and TN F-a were measured. 
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Materials and Methods 
Patients 
Patients had advanced renal cell cancer and participated in an open label 
non-randomized phase I dose escalation trial carried out in two European cancer 
centers to evaluate the safety and tolerability of an initial single injection of 
rHuiL-12 as well as the safety and tolerability of repeated s.c. injections. Toxicity 
analysis of the phase I study had indicated that 0.5 ~g/kg was the maximum 
tolerated dose of a first s.c. injection of rHuiL-12 [Portielje et al, 1999]. 
Parameters of coagulation and fibrinolysis were studied in 18 patients after the 
first subcutaneous injection of rHuiL-12 at a dose of 0.5 ~g/kg. The group 
consisted of 12 males and 6 females with a mean age of 57 years (range 42-70). 
Patients had a World Health Organization (WHO) performance score of 0 to 1, a 
life expectancy ;, 4 months, adequate hematological status and normal renal, 
hepatic, cardiovascular and pulmonary function. Results of routine coagulation 
assays (prothrombin time and activated partial thromboplastin time) were 
normal. All former therapies were ended at least 6 weeks prior to start of treat-
ment with rHuiL-12. Patients did not use systemic corticosteroids or anti-
coagulant drugs. Patients with major concurrent systemic disease were excluded. 
Patients gave informed consent and the ethics committees of participating 
hospitals approved of the protocol. Recombinant human IL-12 (rHuiL-12, Ro 24-
7472) was supplied by Hoffmann La Roche, Nutley, U.S.A, and administered by 
s.c. injection. All patients received the injection at 8.00 a.m. Acetaminophen was 
prescribed to alleviate fever, headache and myalgia. Metoclopramide was 
prescribed in case of nausea and vomiting. No other medications were given 
routinely. 
Collection of blood 
Blood samples for coagulation and cytokine assays and platelet counts were 
obtained directly before and 4, 8, 12, 24, 48 and 72 hours after the first rHuiL-
12 administration (0.5 ~g/kg subcutaneously). In 12 patients blood was also 
obtained after 96 and 168 hours. Blood was drawn through an indwelling 
intravenous infusion needle (Venflon, 16 gauge). Blood for coagulation assays 
was collected in 5 ml siliconized glass tubes containing 10 mM EDTA, 10 mM 
benzamidine and 100 ~g of soybean trypsin inhibitor (type I-S, Sigma chemicals, 
St Louis, USA) (final concentrations) to prevent activation of the complement 
and contact coagulation system. Plasma was obtained by centrifugation of blood 
for 10 minutes at 1300 g. Plasma samples were stored at -70°C until tested. 
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Cytokines and platelet counts were determined in EDTA anticoagulated plasma. 
Blood samples for measurement of prothrombin time (PT) and activated partial 
thromboplastin time (APTT) were obtained before and 24 and 168 hours after 
rHull-12 injection and collected in siliconized glass tubes containing 0.105 M 
sodium-citrate. 
Coagulation and fibrinolysis assays 
Plasmin-a2-antiplasmin (PAP) complexes, reflecting the activation of 
plasminogen, were measured as parameter of fibrinolysis. PAP complexes were 
determined with a radio-immuno assay described elsewhere in detail [Levi et al, 
1992]. Normal values are less than 7 nmol/1. Antigenic levels of tissue type 
plasminogen (tpA) were measured with a previously described sandwich EUSA 
[Zonneveld et al, 1987]. The results of tPA measurements were related to 
standard curves of recombinant tPA, with normal values for tPA below 11 ng/ml. 
Levels of plasminogen-activator inhibitor-! (PAI-I) were assessed with an EUSA, 
that had been modified from a sandwich type radio-immunoassays and has been 
described elsewhere in detail [Boer et al, 1991]. In short, monoclonal anti-PAI-l 
antibody (mAb CLB-2C8) was used as the coating antibody and biotinylated 
polyclonal rabbit anti-PAI-l antibodies as the conjugate. Results were related to 
a standard curve of human PAI-l and normal values were between 30 and 60 
ng/ml. Thrombin-antithrombin III (TAT) complexes were measured with an 
enzyme linked immunosorbent assay described elsewhere in detail [Boermeester 
et al, 1995]. Normal values in this assay were less than 4 ng/ml. 
PT and APTT were measured with a commercially available kit (PT-fibrinogen 
recombinant and APTT-SP (liquid) kit, Instrumentation laboratory, Barcelona, 
Spain). 
Cytokine assays 
Serum concentrations of bio-active IL-12 are measured by a method of 
antibody capture followed by a cell proliferation assay with a lower limit of 
detection of 50 pg/ml [Motzer et al, 1998]. IFN-y and TN F-a concentrations were 
determined with commercially available enzyme amplified sensitivity 
immunoassays (Medgenic EASIA, Biosource Europe, Fleurus, Belgium). Normal 
values of IFN-y are less than 0.2 IU/ml and normal values of TN F-a are less than 
20 pg/ml. The lower limit of detection of the IFN-y assay is 0.03 IU/ml and the 
lower limit of detection of the TN F-a assay is 3 pg/ml. 
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Pharmacologic data analyses 
Individual plasma concentration-time data of cytokines were analysed by 
non-compartmental methods using the Siphar software package (version 4.0; 
SIMED, Creteil, France). Pharmacodynamic analysis of coagulation and 
fibrinolysis modulation by rHu!L-12 was also performed using the Siphar 
software. Total area under the effect curve (AUEC,0,.1 ) for PAP complexes, tPA, 
PAl and TAT complexes were calculated for each patient using the trapezoidal 
rule. The AUECnet , the area under the effect curve above baseline values, was 
calculated by [AUEC,"'' minus AUECoet ]. The baseline levels of PAP complexes, 
tPA, PAl and TAT complexes were obtained from measured predose levels, 
assuming that baseline values would have been maintained for the duration of 
the study in the absence of rHull-12 administration. 
Relationships between the various AUEC," values and between concentration-
time profiles of PAP complexes, tPA, PAl and TAT complexes were evaluated by 
multiple regression analysis. To test parameter differences for statistical 
significance, a two-tailed unpaired Student's t-test was performed. Probability 
values of less than 0.05 were regarded as statistically significant. All calculations 
were performed using Number Cruncher Statistical System (NCSS, version 5.X; 
Dr. Jerry Hintze, Kayesville, UT, USA. 
Results 
Side effects 
Common rHull-12 related side effects and laboratory abnormalities were 
fever, other flu-like symptoms/ nausea, vomiting, fatigue, anemia, leucopenia, 
and hyponatremia. Liver enzymes increased in 7 patients, the maximum increase 
being 5 times the normal level. A more detailed decription of the clinical side 
effects has been given in our report of the phase I study [Portielje et al, 1999]. 
No hemorrhagic or thrombotic complications occurred within the first week after 
administration of the first dose of rHull-12. 
Plasmin-0'2-antiplasmin (PAP) complexes 
Fourteen patients had elevated PAP complexes before rHull-12 
administration with values ranging from 8.7 to 31 nmol/1 (Table 1). After rHull-
12, PAP complexes increased in 17 patients with individual peak concentrations 
reached between 12 and 168 hours (median 72). 
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Figure 1. The effect of IL-12 on the fibrinolytic and coagulation systems. 
Mean ± standard error of the mean {SEM) plasma concentrations of 
plasmin-a2-antiplasmin complexes {A), tissue plasminogen activator (B), 
plasminogen activator inhibitor-1 (C) and thrombin-anti-thrombin III 
complexes (D) during a period of 168 hours after a single subcutaneous 
injection of 0.5 pg/kg IL-12 in 18 patients with advanced renal cell 
carcinoma. Significant differences between base-line concentrations and 
concentrations after IL-12 injection are indicated by an asterix (p< 0.05). 
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The mean concentration of PAP complexes increased from a baseline level of 
11.8 ± 6.6 nmol/1 to a maximum of 18.8 ± 7.4 nmolfl (p=O.OOS). levels slowly 
declined without returning to baseline within the 7 days period of monitoring. 
Figure 1A shows the mean concentration of PAP complexes after rHuiL-12 
injection. PAP levels remained constant in one patient. 
Tissue plasminogen activator (tPA) and plasminogen-activator inhibitor-! (PAl) 
At baseline, tPA levels were increased in 8 patients (range 12 - 24 ng/ml) 
and PAl levels were elevated in 14 patients (range 64 - 278 ng/ml) (Table 1). 
Seven out of 8 patients with baseline elevated tPA levels also had increased 
baseline PAl levels (Table 1). 
The administration of rHuiL-12 induced an increase of circulating tPA in all 
patients, with individual peak concentrations reached between 48 and 168 hours 
(median 72). The mean concentration of tPA increased from a baseline level of 
12.6 ± 5.2 ng/ml to a maximum of 19.0 ± 6.7 ng/ml (p=O.OOS). Thereafter, 
levels slowly decreased but had not reached baseline at 168 hours. At 168 hours, 
with samples available from 12 patients, mean tPA level was 18.3 ± 10.2 ng/ml 
versus a paired mean level of 11.7 ± 4.0 ng/ml (p=0.059) before therapy. 
Notably, in 6 out of 8 patients with increased baseline tPA levels, tPA initially 
decreased after rHull-12, from a mean baseline concentration of 17.7 ± 3.8 
ng/ml to a minimum 9. 7 ± 3.8 ng/ml, but then started to rise at 4 to 12 hours 
(median 8). 
Table 1. Number of patients with elevated baseline levels of 
coagulative and fibrinolytic parameters, IFNy or TNFa and 
median values. 
Parameter 
(normal value*) No. of patients (%) Median value 
TATe ( <4 ng(ml) 4 (22) 56 ng/ml 
PAPc ( <7 nmol/1) 14 (78) 12 nmol(l 
tPA ( <11 ng/ml) 8 (44) 16 ng/ml 
PAI ( 30 - 60 ng(ml) 14 (78) 117 ng/ml 
IFNy ( <0.2 IU/ml) 8 (44) 1.0 IU/ml 
TN Fa ( <20 pg/ml) 14 (78) 31 pg/ml 
*Plasma concentration measured in healthy individuals. 
Range 
30- 189 
8.7- 31 
12-24 
64-278 
0.4- 3.6 
22-83 
64 • Chapter 4 • 
In all 14 patiens with elevated PAI at baseline, levels decreased after rHull-
12, with individual minimum concentrations reached after 4 to 168 hours 
(median 8). PAI levels did not change in the 4 patients with normal levels at 
baseline. The mean concentration of PAl decreased from a baseline level of 111 ± 
69 ng/ml to a minimum of 65 ± 53 ng/ml (p=0.031). After the nadir, PAl levels 
slowly increased but remained below baseline during the whole period of 
monitoring. Figures 16 and c show the mean concentrations of tPA and PAl after 
rHu!L-12 injection. 
Elevation of PAP complexes after rHuiL-12 injection correlated significantly 
with elevation of tPA and reduction of PAI (p=0.0042). 
Thrombin-anti-thrombin III (TAT) complexes 
TAT complexes were measured to assess thrombin generation induced by IL-
12. RHu!L-12 induced a coagulative response in 9 patients (50%), with individual 
peak levels reached between 4 to 72 hours (median 12). The mean concentration 
of TAT complexes increased from a baseline level of 29 ± 53 ng/ml to a 
maximum of 460 ± 322 ng/ml (p=O.OOOl). Four patients had strongly elevated 
levels of TAT complexes before injection of rHu!L-12, with values between 30 
and 189 ng/ml (Table 1). Within 4 hours after administration of rHu!L-12 to 
these patients, TAT complexes further increased, to reach maximal 
concentrations between 551 and 816 ng/ml. Of 14 patients with normal baseline 
levels of TAT complexes, 5 showed increasing levels upon rHull-12 
administration with maximal concentrations of TAT complexes between 19 and 
605 ng/ml. Levels of TAT complexes had normalized in all patients at 24 to 168 
hours (median 48). Notably, although the patients had indwelling catheters, an 
artefactual increase of TAT complexes by these catheters can not explain the 
course of TAT levels, since such an artefactual increase is expected to occur 
immediately after insertion of the catheters. Figure 10 shows the mean 
concentration of TAT complexes after rHull-12 injection. 
In all patients with detectable thrombin generation, peak levels of TAT complexes 
preceded peak levels of PAP complexes. 
Routine clotting parameters 
PT and APTT as well as platelets were measured in all patients. No significant 
changes were noted in PT or APTT values upon rHulL-12 administration. In 
contrast, mean platelet count decreased after rHuiL-12 injection, from 295 ± 99 
at baseline to a minimum of 203 ± 88 million per ml (p=0.008). Individual 
minimum counts were reached after 24 to 96 hours (median 72). Platelet counts 
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had returned to baseline levels at 168 hours. Two patients experienced grade 1 
thrombocytopenia, with platelet counts between 75 and 100 million per mi. 
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Figure 2. Plasma concentrations of IL-12, IFN-r and TNF-a after IL-12 
injection. 
Mean ± standard error of the mean (SEM) plasma concentrations of rHuiL-
12 (A), IFNr (B) and TNFa (C) during a period of 168 hours after a single 
subcutaneous injection of 0.5 pgjkg IL -12 in 18 patients with advanced renal 
cell carcinoma. Significant differences between base-line concentrations and 
concentrations after IL-12 injection are indicated by an asterix (p< 0.05). 
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Cytokines 
Blood samples for IL-12 measurements were available from 17 patients. 
Before injection, serum IL-12 levels were below the detection limit in all patients. 
After injection, the mean concentration of IL-12 increased to 269 ± 291 pg/ml. 
Individual peak levels of rHuiL-12 were reached after 4 to 24 hours (median 12). 
Figure 2A shows mean levels of IL-12. 
At base-line IFN-y concentrations were increased in 8 patients with values 
between 0.4 and 3.6 IU/ml (table 1). IFN-y increased in all patients, with 
individual maximum concentrations reached after 12 to 48 hours (median 24). 
The mean concentration increased from 0.8 ± 0.9 IU/ml to a maximum of 8.7 ± 
12.4 IU/ml (p= 0.025). Thereafter IFN-y slowly decreased to reach baseline 
levels at day 7 of observation. Base-line TN F-a concentrations were increased in 
14 patients with values between 22 and 83 pg/ml (table 1). 
In response to rHulL-12, TNF-a levels increased in all patients with individual 
maximum levels reached after 24 to 72 hours (median 48). The mean plasma 
concentration increased from 33.5 ± 20.7 pg/ml to a maximum of 92.9 ± 21.8 
pgjml (p< 0.00001). Figures 2B and C show mean levels of IFN-y and TNF-a 
after rHuiL-12 administration. 
Serum concentrations of rHulL-12 and pattern and height of IFN-y and TN F-a 
induction were not different for patients with and without detectable thrombin 
response. 
Discussion 
IL-12 induced sustained activation of fibrinolysis in the majority and 
substantial thrombin generation in half of the patients. While the endothelium 
was stimulated to produce tPA, secretion of its natural inhibitor PAI-l decreased. 
This opposite behaviour of tPA and PAI-l, as far as we know unique for IL12, 
probably explained the observed plasminogen activation. The fibrinolytic 
response continued at the time thrombin generation had already abated and, 
therefore, occurred independently, as has previously been observed in 
experimental endotoxemia [Van der Poll et al, 1991]. 
Coagulative and fibrinolytic responses to IL-12 have only been studied in 
chimpanzees. There, TAT complexes reached a plateau between 8 to 48 hours 
after intravenous administration and PAP complexes were maximal at the last 
sampling point at 48 hours, indicating a similar sustained response. 
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The mechanism by which IL-12 influences coagulation and fibrinolysis 
remains to be elucidated. Although many biological effects can be attributed to 
the induction of IFN-y, this seems not a key mediator here. Not only were IFN-y 
levels the same for patients with and without thrombin generation, the peak of 
the coagulative response preceded maximal IFN-y levels by 12 hours. In in-vitro 
models, IFN-y inhibited PAI-l production by endothelial cells and suppressed PAI-
l mRNA expression [Gallacchio et al, 1996; Siren et al, 1994]. The literature 
yields conflicting reports on the in-vivo effects of IFN-y: In dermatitis patients, 
IFN-y inhibited fibrinolysis by suppressing the release of tPA and stimulating PAL 
Concomitantly TAT complexes increased [Musial et al, 1998]. In patients with 
severe injuries, with baseline elevation of markers of both coagulation and 
fibrinolysis, IFN-y did not further affect these systems [Dries et al, 1998]. Neither 
seems TNF-a the mediator of the observed effects. The height of TNF-a levels 
and the coagulative response were not correlated, and TNF-a peaked when 
thrombin response had completely extinguished. With regard to fibrinolysis, TNF-
a administration was associated with a rapid early activation, unlike the response 
we observed [Van der Poll et al, 1991]. Also, in chimpanzees, induction of 
coagulation and fibrinolysis after IL-12 occurred without detectable TNF-a 
induction [Lauw et al, 1999]. Furthermore, in experimental endotoxemia in 
humans, thrombin generation was not affected by anti-TNF [Van der Poll et al, 
1994a]. Apparently TN F-a does not always induce a coagulative response in vivo 
[Van der Poll et al, 1990]. 
Compatible with the observation that patients with malignancies frequently 
have activation of systemic coagulation and fibrinolysis [Zacharski et al, 1992], 
the majority of our patients had elevated baseline levels of the markers of 
fibrinolysis and coagulation. Moreover, alterations in the plasminogen activator-
plasmin proteolytic systems appear to be essential events in tumor progression 
[Mignatti and Rifkin, 1993]. In a study with IL-6, patients with metastatic RCC 
had comparable elevated baseline levels of PAP complexes, PAl and tPA 
[Stouthard et al, 1996]. However, baseline levels of TAT complexes were 
considerably lower. Whether this difference refiects different tumor load is 
unclear. 
IL-12 induced fibrinolytic and coagulative responses that are completely 
different from those induced by other cytokines. As opposed to other cytokines, 
thrombin generation preceded maximal fibrinolysis [Van der Poll et al, 1990 and 
1991; Baars et al, 1992; Levi et al, 1993 and 1994]. Additionally, the coagulative 
and fibrinolytic responses were delayed and the duration of the fibrinolytic 
response was exceptionally long. For example, interleukin-2 and TNF-a caused 
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activation of coagulation and fibrinolysis within 6 hours after administration 
[Baars et al, 1992; Fleischmann et al, 1991; Van der Poll et al, 1990; 
Boermeester et al, 1995]. The subcutaneous route of administration may in part 
explain the delayed effects of IL-12, but intravenous administration also induced 
a prolonged activation of fibrinolysis [Lauw et al, 1999]. This protracted effect of 
IL-12 may be related to its relatively long half-life. While cytokines 
characteristically have a plasma half-life of less than 30 minutes, IL-12 has a 
half-life of more than 5 hours [Atkins et al, 1997; Portielje et al, 1999]. 
The clinical relevance of the observed effects of IL-12 on fibrinolysis and 
coagulation cannot be distilled from our data. No hemorrhagic or thrombotic 
complications occurred in our study. However, in previous studies several 
bleeding episodes were mentioned. When 0.5 11g/kg of intravenous IL-12 was 
administered on 5 consecutive days as part of a phase II study, 2 patients had 
gastrointestinal bleeding that complicated ulceration of the large intestine and 
died [Leonard et al, 1997]. In the preceding phase I study, 2 out of 12 patients 
treated with the same dose experienced severe gastrointestinal hemorrhage 
[Atkins et al, 1997]. An additional gastrointestinal bleeding episode was 
observed in a study with subcutaneous IL-12 [Motzer et al, 1998]. No details 
were provided concerning coagulation tests or platelet counts. Although 
inflammation and ulceration of the lining of the gastrointestinal tract are 
considered to be IL-12 related side effects, it can not be excluded that coexisting 
coagulation abnormalities prompted hemorrhage from the damaged mucosa. 
We can only speculate whether stimulation of fibrinolysis contributes to the anti-
tumor effect of IL-12. IL-12 is supposed to have an inhibitory effect on tumor-
angiogenesis, though the underlying mechanism is yet unknown [Voest et al, 
1995; Sgadari et al, 1996] Our results indicate that IL-12 inhibits PAI-l 
production. Tumor-angiogenesis has recently been shown to be PAI-l dependent 
and the increased PAI-l levels in cancer patients appear to be causally 
contributing to tumor invasion [Bajou et al, 1998]. Further studies should reveal 
whether the observed fibrinolytic responses may result in inhibition of tumor 
angiogenesis. 
In conclusion, we have shown that administration of IL-12 can induce 
sustained activation of the fibrinolytic system and a substantial thrombin 
generation. The timing and duration of these processes differ from those 
observed with other cytokines. Further investigations are needed to elucidate the 
mechanism behind these changes and the relation to anti-tumor and side effects. 
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Subcutaneous injection of Il-12 induces systemic 
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Abstract 
IL-12 is a cytokine with important regulatory functions bridging innate and 
adaptive immunity. IL-12 has been proposed as an immune adjuvant for 
vaccination therapy of infectious diseases and malignancies. The inflammatory 
signals mediated by IL-12 can play an important role in the adjuvant effect, but 
at the same time may constitute a risk for side effects. 
In the setting of a phase I study, we studied the effect of different doses of 
s.c. administered recombinant human IL-12 in 26 patients with advanced renal 
cell carcinoma, and now demonstrate that IL-12 induces dose-dependent 
systemic activation of multiple inflammatory mediator systems in humans. 
Previously we have shown that the maximum tolerated dose of IL-12, i.e. 0.5 
!lg/kg, induced a significant coagulative response, here we demonstrate that this 
dose also induces degranulation of neutrophils: plasma levels of elastase 
(azurophilic granules) and lactoferrin (specific granules) increased from 48 ± 17 
ng/ml (mean± standard deviation) to 117 ± 136 ng/ml (p < 0.05) and from 124 
±51 ng/ml to 181 ±82 ng/ml (p;O.Ol), respectively, at 24 hours. Additionally, IL-
12 injection mediated the release of lipid mediators: Plasma concentrations of 
secretory phospholipase A2 (sPLA2) increased from 17 ± 20 ng/ml to 97 ± 113 
ng/ml (p;0.003). Systemic activation of inflammation and coagulation by IL-12 
occurred in a dose dependent way. At 0.1 !lg/kg of IL-12, systemic responses 
were minimal: Although mild activation of neutrophils was already detectable, 
activation of the coagulative response did not yet occur, and activation of 
fibrinolysis and formation of sPLA2 were limited. Because s.c. injection is a 
common route of administration for immune adjuvants, we suggest that IL-12 as 
adjuvant should not be given at doses higher than 0.1 Jlg per kg in order to avoid 
severe systemic inflammatory responses. 
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Introduction 
lnterleukin 12 (IL-12) is a cytokine with important immune-regulatory 
functions. IL-12 stimulates T-cells and NK-cells to produce IFN-y and increases 
cytotoxic activity by NK-cells. Additionally IL-12 stimulates the helper activity of 
CD4 T-cells towards cellular immune responses and enhances antigen specific 
CDS+ T cell responses [Trinchieri, 1998]. As a stimulator of the cellular immune 
response, IL-12 has potential efficacy in malignant, infectious and allergic 
diseases. Studies of systemic cytokine therapy with IL-12 have been performed 
in different types of cancer, asthma and viral hepatitis [Carreno et al, 2000; 
Hurteau et al, 2001; Bryan et al, 2000; Portielje et al, 1999; Atkins et al, 1997; 
Motzer et al, 1998 and 2001; Leonard et al, 1997]. However, IL-12, administered 
either intravenously or subcutaneously, had disappointing efficacy but substantial 
toxicity. Recently, it was proposed that IL-12 may be an effective immune 
adjuvant for vaccination therapy of infectious diseases and malignancies 
[Gherardi et al, 2001; Rodolfo et al, 1999; Buchanan et al, 2001]. The 
immunological mechanisms underlying the adjuvant efficacy of IL-12 are not 
fully defined. Classical adjuvant substances are strong stimulators of local 
inflammation and the pro-inflammatory characteristics of IL-12 are thought to 
contribute to its adjuvant effects. Similar to other adjuvants, the subcutaneous 
route also appears appropriate for IL-12 for this purpose. 
Polymorphonuclear neutrophils (PMN) are important effectors of the 
inflammatory response since they release toxic compounds such as proteases 
upon activation, that damage the microenvironment. We do not know whether or 
not IL-12 activates neutrophils in humans. Few preclinical studies have 
addressed the effects of IL-12 on PMN. Following administration of IL-12 to 
chimpanzees, degranulation of PMN was observed [Lauw et al, 1999]. In-vitro 
studies have revealed that PMN express IL-12 ~1 receptors and that binding of 
IL-12 results in actin polymerization and a concentration dependent increase in 
reactive oxygen metabolites in PMN [Collison et al, 1998]. In addition to potential 
direct effects through IL-12 receptor engagement, IL-12 could also exert indirect 
effects on PMN through the induction of other pro-inflammatory cytokines such 
as TNF-a, IL-6 or IL-8. The degranulation of PMN in various physiological 
situations is appropriately reflected by levels of elastase-a1-antitrypsin 
complexes and lactoferrin in the peripheral blood [Van der Poll et al, 1994a 
1994b; Nuijens et al, 1992; Suffredini et al, 1989]. Elastase is a proteinase 
released from azurophilic granules of neutrophils that rapidly forms complexes 
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with its natural inhibitor a1-antitrypsin, while lactoferrin is derived from the 
specific granules [Weiss, 1989]. 
The increased release of secretory phospholipase A2 (sPlA2) from endothelial 
and other cells is considered as another component of the inflammatory cascade 
[Pruzanski & Vadas, 1991]. PLA2 is a lipolytic enzyme that releases fatty acids, 
often arachidonic acid, from membrane phospholipids for production of important 
lipid mediators such as tromboxane A2, prostaglandins, leukotriens and platelet 
activating factor [Crowl et al, 1991]. PlA2 is thought to promote phagocytosis of 
injured cells and tissue debris, thereby enhancing inflammation [Pruzanski & 
Vadas, 1991; Hack et al, 1997]. During inflammatory reactions plasma levels of 
sPlA2 may markedly increase up to 100-fold over base-line. 
At present there are no data regarding the potential of locally injected IL-12 to 
induce systemic inflammatory responses in humans. We performed a phase I 
study with Il-12 in patients with advanced renal cell cancer [Portielje et al, 
1999]. In the present analysis, we address systemic inflammatory and 
coagulation responses in these patients. Our results show that Il-12 dose-
dependently triggers these responses. These data may be useful for the design 
of studies in which Il-12 is used as an adjuvant. 
Materials and Methods 
Patients 
We studied 26 patients with advanced renal cell cancer which participated in 
a phase I dose escalation trial carried out in the Rotterdam and Mainz cancer 
centers to evaluate the safety and tolerability of s.c. administered rHuiL-12. 
Toxicity analysis of the phase I study indicated that 0.5 ~g/kg was the maximum 
tolerated dose of the first s.c. injection of rHuiL-12 [Portielje et al, 1999]. We 
studied markers of PMN degranulation in these patients after the first s.c. 
injection of rHuiL-12 at a dose of 0.1 ~g/kg (n=3), 0.5 ~g/kg (n=19) or 1.0 
~g/kg (n=4). Prior to treatment, patients had a World Health Organization 
(WHO) performance score of 0 to 1, and adequate hematological, renal, hepatic, 
cardiovascular and pulmonary functions. All former therapies were terminated at 
least 6 weeks prior to start of treatment with rHuiL-12. The patients did not use 
systemic corticosteroids. Patients with concurrent systemic disease were ex-
cluded. Patients gave informed consent and the ethics committees approved of 
the protocol. Recombinant human IL-12 (rHuiL-12, Ro 24-7472) was supplied by 
Hoffmann La Roche (Nutley, NJ) and administered by s.c. injection. All injections 
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were given at 8.00 a.m. Acetaminophen was prescribed to alleviate fever, 
headache and myalgia. Metoclopramide was prescribed in case of nausea and 
vomiting. No other medications were given routinely. 
Blood sampling and assays 
Blood samples for elastase-a1-antitrypsin complexes, lactoferrin and sPlA2 
measurement were obtained directly before and 4, 8, 12, 24, 48 and 72 hours 
after the first rHuiL-12 administration. In 12 patients blood was also obtained 
after 96 and 168 hours. Blood was drawn through an indwelling intravenous 
infusion needle (Venflon, 16 gauge). Plasma was obtained by centrifugation of 
blood for 10 minutes at 1300g. Plasma samples were stored at -70°C until 
tested. All assays were done with EDTA anti-coagulated plasma. Plasma levels of 
elastase-a1-antitrypsin complexes and lactoferrin were assayed by RIA as 
described in detail previously [Nuijens et al, 1992]. Briefly, sepharose beads, to 
which polyclonal antibodies against human elastase or a mAb against human 
lactoferrin were coupled, were incubated with the samples to be tested. Elastase-
a1-antitrypsin or lactoferrin bound to the beads was quantitated by incubation 
with 1251-mAb against complexed a1-antitrypsin (RIA for elastase-a1-antitrypsin) 
or polyclonal 125I-antilactoferrin (RIA for lactoferrin). Results were expressed as 
nanograms of elastase complexes or lactoferrin per mi. by reference to standard 
curves. The lower limit of detection of elastase-a1-antitrypsin complexes is 25 
ngjml; normal values are less than 100 ng/ml. The lower limit of detection of 
lactoferrin is 100 ng/ml; normal values are less than 400 ng/ml. 
Secretory phospholipase A2 (sPlA2) concentrations in plasma were 
determined with an ELISA that was modified from that reported by Smith [Smith 
et al, 1992]. MAbs against human sPlA2 type II (provided by Dr. F.B. Taylor Jr., 
Oklahoma Medical Research Foundation, Oklahoma City, OK, USA) were used as 
the coating and catching antibodies, respectively. Results are expressed by 
reference to a standard curve consisting of a dilution of culture supernatant of 
HepG2 cells stimulated with IL-6, in which the amount of sPlA2 was assessed by 
comparison with recombinant human secretory-type PlA2 (sPlA2; courtesy of 
Prof. H .M. Verheij, Department of Enzymology and Protein Engineering, 
University of Utrecht, Utrecht, The Netherlands). The lower limit of detection of 
this assay is 0.2 ng/ml. Normal values are less than 5 ng/ml. 
Serum concentrations of bio-active IL-12 were measured by a method of 
antibody capture followed by a cell proliferation assay with a lower limit of 
detection of 50 pg/ml [Motzer et al, 1998]. Samples for IL-12 determination 
were available from 25 patients [Portielje et al, 1999]. IFN-y, TNF-a, IL-10, IL-8, 
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and Il-6 concentrations were detenmined with commercially available enzyme 
amplified sensitivity immunoassays (Medgenic EASIA, Biosource Europe, Fleurus, 
Belgium). The lower limits of detection of the assays were: IFN-y: 0.03 IU/ml; 
TNF-a: 3 pg/ml; Il-10: 1 pg/ml; Il-8: 1 pg/ml; Il-6: 2 pg/ml and Il-4: 0.2 
pg/ml. Cytokine concentrations were measured as part of previous [Portielje et 
al, 1999] and ongoing studies and results from patients treated at dose level 0.5 
fig/kg rHuiL-12 are presented here to enable definition of the relationship 
between cytokine concentrations and inflammatory parameters. Blood samples 
for determination of absolute numbers of peripheral-blood polymorphonuclear 
neutrophils (PMN's) were available from 20 patients and collected directly before 
and 1, 2, 3, 4 and 7 days after the first administration of rHull-12. PMN counts 
were detenmined in EDTA anti-coagulated blood samples using a Technicon H1 
automated cell counter (Technicon, Tarrytown, NY, USA). 
Plasmin-a2-antiplasmin (PAP) complexes, were measured as parameter of 
fibrinolysis. PAP complexes were determined with a radio-immuno assay 
described elsewhere in detail [levi et al, 1992]. Normal values are less than 7 
nmoljl. Thrombin-antithrombin III (TAT) complexes were measured with an 
enzyme linked immunosorbent assay described elsewhere in detail [Boermeester 
et al, 1995]. Normal values in this assay were less than 4 ng/ml. 
Pharmacologic data analyses 
Individual plasma concentration-time data of cytokines were analysed by 
non-compartmental methods using the Siphar software package (version 4.0; 
Inna Phase, Philadelphia, PA, USA). Pharmacodynamic analysis of the modulation 
of leucocyte counts, PMN degranulation products and sPLA2 induction by rHuil-
12 was also performed using the Siphar software. Total area under the effect 
curve (AUECtotol ) for elastase-a1-antitrypsin complexes, lactoferrin, and sPLA2 
was calculated for each patient using the trapezoidal rule. The AUEC,,,, the area 
under the effect curve above baseline values, was calculated by [AUECeotal minus 
AUEC,,]. The baseline levels of elastase-a1-antitrypsin complexes, lactoferrin 
and sPLA2 and the baseline leucocyte counts were obtained from measured pre-
dose levels and counts, assuming that baseline values would have been 
maintained for the duration of the study in the absence of rHuil-12 
administration. 
Relationships between the various AUEC,, values and between concentration-
time profiles of elastase-al-antitrypsin complexes, lactoferrin and sPLA2 were 
evaluated by multiple regression analysis. To test parameter differences for 
statistical significance in the paired samples, a two-tailed paired Student's t-test 
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was performed. To test parameter differences for statistical significance in the 
unpaired samples, a two-tailed unpaired Student's t-test was performed. 
Probability values of less than 0.05 were regarded as statistically significant. All 
calculations were performed using Number Cruncher Statistical System (NCSS, 
version 5.X; Dr. Jerry Hintze, Kayesville, UT, USA). 
Results 
Neutrophil numbers 
RHuiL-12 induced depression of the number of peripheral blood PMN in all 
patients. After injection of 0.1 [.lg/kg rHu!L-12, PMN decreased from 4.0 x 109/1 
to 0.94 x 109/1 (n~1). Figure 1 shows that after injection of 0.5 [.lQ/kg rHuiL-12 
(n~15), PMN decreased from 4.55 ± 1.32 x 109/1 (mean ±standard deviation) to 
1.74 ± 0.84 X 109/1 (p < 0.001). 
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Figure 1. Neutrophil counts after subcutaneous Il-12. 
Mean ± standard error of the mean {SEM) neutroPhil counts during a period 
of 168 hours after a single subcutaneous injection of 0.5 pg/kg IL-12 in 14 
patients with advanced renal cell carcinoma. Significant differences between 
base-line concentrations and concentrations after IL-12 injection are 
indicated by an asterix (p<O.OS). 
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Finally, after injection of 1.0 ll9/kg rHull-12 (n=4), PMN decreased from 
3.9 ± 1.14 x 109/1 to 1.45 ± 0.33 x 109/1. After 0.5 llg/kg rHull-12, PMN nadir 
occurred after a median of 3 days (range: 2-4) while after 1.0 llg/kg rHull-12, 
PMN nadir occurred after a median of 4 days (range: 4-7). At dose levels 0.5 and 
1.0 llg/kg rHull-12, PMN remained significantly below baseline values (p< 
0.001) during the whole 7- day observation period. 
PMN degranulation 
RHull-12 administration resulted in degranulation of PMN, reflected by (i) 
increased plasma levels of elastase-a1-antitrypsin complexes, which reflect the 
degranulation of azurophilic granules and (ii) increased plasma levels of 
lactoferrin, which reflect the degranulation of specific granules (figure 2). 
Elastase-a1-antitrypsin complexes increased in all patients and increases 
were rHull-12-dose dependent (table 1). At doses of 0.1 and 0.5 llg/kg rHull-
12, elastase-al-antitrypsin complexes peaked after a median of 48 hours 
(range: 8-72), whereas at doses of 1.0 llQ/kg rHull-12, maximum 
concentrations were reached after a median of 60 hours (range: 48-72). Plasma 
concentrations of lactoferrin increased in 23 out of 26 patients (89%). Individual 
maximum plasma concentrations of lactoferrin varied considerably among 
patients and patients with low baseline levels tended to have relatively low peak 
levels as well. 
At doses of 0.1 and 0.5 ll9/kg rHull-12, lactoferrin peaked after a median of 
24 hours (range: 4-96), whereas at doses of 1.0 ll9/kg rHull-12, maximum 
concentrations of lactoferrin were reached after a median of 60 hours (range: 
48-72). Elevation of elastase-a1-antitrypsin complexes after rHull-12 injection 
correlated significantly with elevation of lactoferrin levels (r = 0.24, p=0.03). 
Plasma concentrations of sPLA2 
Levels of circulating sPI.A2 were measured as an indirect parameter for the 
formation of lipid mediators such as tromboxane A2, prostaglandins, leukotriens 
and platelet activating factor. 
RHull-12 induced an increase of circulating sPLA, in 25 of 26 patients and 
elevation was Il-12 dose dependent (table 1). Nine patients had elevated sPI.A, 
concentrations before rHull-12 administration, with values ranging from 6.9 to 
63 ng/ml. Patients with elevated baseline concentrations had significantly higher 
peak levels than patients with normal baseline levels (205 ± 149 (mean ± 
standard deviation) versus 31 ± 17, p < 0.01). Figure 3 shows the mean 
concentration of sPI.A2 complexes after 0.5 llg/kg rHu!l-12. 
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The median time to peak concentration was 48 hours after a dose of 0.1 and 
0.5 Jl9/kg rHulL-12, and 72 hours after a dose of 1.0 Jl9/kg. Individual peak 
concentrations were reached between 48 and 168 hours. Levels slowly declined 
to baseline within the 7 days of observation. 
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Figure 2. Neutrophil degranulation after subcutaneous n.-12. 
Mean ± standard error of the mean (SEM) plasma concentrations of 
elastase-al.-antitrypsin complexes (A) and lactoferrin (B) during a period of 
168 hours after a single subcutaneous injection of 0.5 pg/kg IL -12 in 19 
patients with advanced renal cell carcinoma. Significant differences between 
base-fine concentrab"ons and concentrations after IL -12 injection are 
indicated by an asterix (p<0.05). 
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Figure 3. Plasma concentrations of secretory phospholipase A2 (sPLA2) after 
subcutaneous IL-12. 
Mean ± standard error of the mean (SEM) plasma concentrations of sPLA2 
during a period of 168 hours after a single subcutaneous injection of 0.5 
pg/kg IL-12 in 19 patients with advanced renal cefl carcinoma. Significant 
differences between base-line concentrations and concentrations after IL -12 
injection are indicated by an asterix (p<O.OS). 
Coagulation and fibrinolysis 
Plasmin-a2-anti-plasmin (PAP) complexes were measured as a parameter for 
the activation of plasminogen. Rhull-12 administration resulted in activation of 
fibrinolysis in all patients with ll-12 dose dependent elevation of plasma 
concentrations of PAP complexes (table 1). PAP complexes peaked after a 
median of 72 hours (range: 12-168). Thereafter, levels slowly declined, but did 
not reach baseline within the first week after rHull-12 administration. 
Table 1. Circulating inflammatory parameters after subcutaneous administration of rHuiL-12 
Elastase-al-ATe 
(<lOOng/ml) 
Lactoferrin ( <400ng/ml) 
sPLA, ( <5ng/ml ) 
PAPc ( <7nmol/l} 
TATe ( <4ng/ml) 
Baseline 
(all) 
Mean 
46 
122 
14 
10.5 
29 
ot. Maximum mean values are shown. 
* p < 0.05, versus baseline 
SD 
16 
45 
18 
6.2 
66 
0.1 ~g/kg 
(n=3} 
Mean"' 
87 
197 
23 
15 
# 
#No TATe responses occurred at a dose of 0.1 rtg/kg rHuiL-12 
SD 
35 
85 
17 
4.0 
0.5 flQ/kg 
(n=19) 
Mean"' 
117* 
181* 
97* 
18.8* 
460* 
SD 
136 
82 
113 
7.4 
322 
1.0 ~g/kg 
(n=4) 
Mean"' 
202* 
248 
144 
27* 
571 
SD 
79 
112 
99 
7.5 
554 
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Elevated thrombin-anti-thrombin Ill (TAT) complexes reflect activation of 
coagulative pathways. A coagulative response was not observed at 0.1 ~g/kg 
rHull-12. However, at 0.5 ~g/kg and 1.0 ~g/kg rHull-12, half of patients had a 
coagulative response (table 1), with TAT complexes reaching mamimum values 
after a median of 12 hours (range: 4-72). 
Table 1 shows maximum mean concentrations of PAP- and TAT complexes 
after different doses of rHull-12. The results of measurement of PAP- and TAT 
complexes of 19 patients that received 0.5 ~g/kg rHIL-12 have been reported 
previously [Portielje et al, 2001]. Because the hemostatic mechanism is tightly 
linked to the inflammatory cascade, we now provide data from patients treated 
at other dose levels as well, in order to gain insight in the dose response 
relationship beween rHull-12 and parameters of systemic fibrinolysis and 
coagulation. 
Cytokines 
Plasma concentrations ol IL-12, TNF-a, IL-6 and IL-8 after IL-12 are shown 
in figure 4. 
Blood samples for IL-12 measurements were available from 18 patients 
treated at dose level 0.5 ~g/kg rHull-12. Serum IL-12 levels were below the 
detection limit in all patients before injection. After administration of rHull-12, 
plasma concentrations increased in 10 patients, with individual peak levels 
reached after 4 to 24 hours (median 12). Mean plasma IL-12 increased to 294 ± 
218 pg/1. After administration of 0.5 ~g/kg rHull-12, TN F-a levels increased in all 
patients, from a mean plasma concentration of 34 ± 20 pg/ml to a maximum of 
93 ± 22 pg/ml (p< 0.00001). Baseline TN F-a concentrations were increased in 15 
out of 19 patients with values between 22 and 83 pg/ml. Individual maximum 
levels were reached after 24 to 72 hours (median 48). The mean plasma 
concentration of IL-8 increased from 17 ± 18 pg/ml to a maximum of 34 ± 27 
pg/ml (p< 0.01) at 48 hours. The mean concentration of IL-6 increased from 24 
± 28 pg/ml to a maximum of 84 ± 72 pg/ml (p< 0.01) at 12 hours. 
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Figure 4. Plasma concentrations of IL-12, TNF-a:, n.-6 and n.-8 after 
subcutaneous ll-12. Mean ± standard error of the mean (SEM) plasma 
concentrations of rHuiL-12, TNFa, IL-6 and IL-8 during a period of 168 
hours after a single subcutaneous injection of 0.5 pg/kg IL-12 in 19 patients 
with advanced renal cell carcinoma. Significant differences between base-
line concentrations and concentrations after IL -12 injection are indicated by 
an asterix (p<O.OS). 
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Discussion 
The present results demonstrate that s.c. Il-12 induces a dose dependent 
systemic activation of multiple inflammatory mediator systems in humans. Il-12 
induced activation and degranulation of PMN in a dose dependent way in patients 
with advanced renal cell cancer. The activation of PMN was sustained, with 
ultimate normalization of plasma levels of degranulation products after 7 days. 
The effect of Il-12 on PMN degranulation is consistent with a study in 
chimpanzees that described PMN activation with maximum elastase-o:1-
antitrypsin complex concentrations at the last plasma sampling time-point of 48 
hours [lauw et al, 1999]. 
Since PMN express functional Il-12 receptors, degranulation may result from 
direct interaction with Il-12. This is supported by in vitro experiments showing 
that Il-12 upon binding increases intracellular free calcium, and induces actin 
polymerization, tyrosine phosphorylation and production of reactive oxygen 
radicals and platelet activating factor in PMN [Collison et al, 1998; Bussolati et 
al, 1998]. In our study, maximal concentrations of products of PMN 
degranulation in the peripheral blood coincided with peak levels of Il-12, i.e. at 
24 hours post injection. In addition, Il-12 may activate PMN indirectly. We 
observed a dose-dependent induction of Il-6, Il-8 and TNF-o: after IL-12 
administration, and these cytokines all have known PMN-activating effects. 
However, our results suggest that PMN degranulation after Il-12 administration 
in vivo is probably not mediated by TNF-o: or IL-8. In humans, TNF-o: induces a 
very rapid degranulation of PMN, with maximum blood levels of elastase-o:1-
antitrypsin complexes and lactoferrin, 3 hours after TNF-o: administration [Van 
der Poll et al, 1992]. In the present study maximum levels of both elastase-o:1-
antitrypsin complexes and lactoferrin were however reached at 24 hours, whilst 
TN F-a: peaked at 48 hours, following injection of Il-12. Similarly, Il-8 is a strong 
PMN activator [Peveri et al 1994; Schroder et al, 1987; Downey, 1994] but 
again, peak plasma concentrations of Il-8 were observed 24 hours after levels of 
the degranulation products elastase-o:1-antitrypsin complexes and lactoferrin 
reached their maximum. The assumption that Il-8 induction did not contribute to 
PMN degranulation is further supported by the observation that, whilst 
administration of IL-1~ to humans induced elevation of Il-8 to levels similar to 
those observed in the present study, degranulation of PMN did not occur [Ogilvie 
et al, 1996]. Il-6 is another potential in vivo mediator of PMN activation after Il-
12. PMN express IL-6 receptors [Keller et al, 1996] and Il-6 exposure has 
previously been shown to induce elastase and lactoferrin release and production 
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of platelet activating factor and oxygen-free radicals by PMN in vitro [Borish et al, 
1989; Biffi et al, 1996]. In our study, peak levels of Il-6 at 12 hours post 
injection preceded peak levels of lactoferrin and elastase-a1-antitrypsin 
complexes at 24 hours post Il-12 injection. This result is consistent with the 
possibility that IL-6, formed in response to Il-12 injection in turn contributes to 
rhe release of elastase-a1-antitrypsin complexes and lactoferrin into the 
circulation. However/ in a chimpanzee model of endotoxemia, in which IL-12 is 
an important mediator of the inflammatory response, PMN degranulation occurs 
independently of TNF-a, Il-8 and Il-6 synthesis [Kuipers et al, 1994]. These 
results indicate that IL-12 potentially activates PMN directly as well as indirectly. 
Il-12 was also a powerful stimulus for the synthesis of the secretory 
phospholipase A2 (sPLA2 ), the enzyme that generates arachidonic acid and thus 
catalyzes the rate limiting step in the formation of lipid mediators. Endothelial 
cells, considered the most important source of sPLA2 in the peripheral blood, 
have not been shown to express Il-12 receptors. IL-6 and TN F-a are the possible 
mediators of sPLA2 synthesis after Il-12 injection, since either cytokine 
stimulates the production and release of sPLA2 in-vitro by various cell types, 
including liver cells, endothelial cells and macrophages [PFeilschifter et al, 1993; 
Redl et al 1993]. In healthy volunteers, TNF-a infusion resulted in increased 
sPLA2 , with maximum plasma levels after 6 hours [Van Dullemen et al, 1989]. 
Interestingly, the anti-tumor effect of TNF-a in a variety of tumor cell models 
depends on cytolysis that requires the activation of sPLA2 by TN F-a [Mutch et al, 
1992]. Furthermore, increased sPLA2 synthesis after Il-12 may play an 
important role in inflammatory colitis, a life threatening side effect observed with 
systemic Il-12 administration [leonard et al, 1997], as can be concluded from 
the observation that IL-12 does not cause gastrointestinal toxicity in a sPLA2 
deficient strain of mice [Car et al, 1999]. Presumably, this lack of toxicity in 
deficient mice is due to the lack of prostanoid contribution to tissue injury. 
In accordance with previous clinical results [Atkins et al, 1997; Bajetta et al, 
1998] we observed a rapid, Il-12-dose dependent, decrease of PMN in the 
peripheral circulation, with protracted depression of cell counts during the whole 
7-day period of observation. Similar to humans, Il-12 administration to mice 
caused decreased numbers of circulating leucocytes and neutrophils [Eng et al, 
1995; Romani et al, 1995]. The decreased PMN counts in the peripheral blood 
after Il-12 administration to humans is thought to occur due to compartmental 
cellular shift with accumulation of cells in liver, spleen and tumor sites. In vitro, 
Il-12 serves as a chemotactic stimulus for human PMN's [AIIavena et al, 1994] 
and Il-12-induced platelet activating factor is thought to play a critical role in 
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this effect [Bussolati et al, 1998]. Il-12 potentially mediates PMN chemotaxis 
through the induction of TN F-a and Il-8. TN F-a upregulates adhesion molecules 
on endothelial cells and can mediate the migration of PMN's [Carlos et al, 1997; 
Bevilacqua et al, 1989; Pober et al, 1986]. In healthy individuals, intravenous 
TNF-o; administration results in short-lived neutropenia, followed within an hour 
by a 24-hour lasting neutrophilia [Van de Poll et al, 1992]. Il-8 is a member of 
the a-chemokine family and an important PMN chemotactic factor [Schroder et 
al, 1987; Van Damme, 1991]. Intravenous injection of Il-8 in mice, resulted in 
an instant neutropenia, followed by profound neutrophilia for several hours 
[Pruijt et al, 1999]. The protracted elevation of TN F-a and Il-8 levels observed 
after Il-12 injection, i.e. lasting for more than 7 and more than 2 days, 
respectively, may well be responsible for the protracted neutropenia observed in 
our patients. 
Clinical studies have addressed the systemic administration of Il-12 in 
patients with asthma, infectious diseases and cancer, but associated toxicity in 
combination with a lack of encouraging clinical results hamper further 
development of Il-12 in this line [Carreno et al, 2000; Hurteau et al, 2001; 
Bryan et al, 2000; Motzer et al, 2001]. More recently, the therapeutic application 
of IL-12 as an immune adjuvant in cancer and infectious diseases has received 
attention. Preclinical results have demonstrated that Il-12 provides a critical 
third signal along with antigen and Il-2 to activate CDS+ T cells [Curtsinger et 
al, 1999]. In addition, Il-12 has an adjuvant effect in the activation of CDS+ T 
cell responses to antigenic peptides in mice [Fallarino et al, 1999]. The 
immunological mechanisms underlying the adjuvant efficacy of Il-12 are 
incompletely understood. Here we show that locally injected Il-12 can activate 
PMN's which are thought to be engaged in a complex cross-talk, with immune 
and endothelial cells that bridges innate and adaptive immunity [Colombo et al, 
1992; DiCarlo et al, 2001]. In particular, Il-12 has strong inflammatory effects 
in-vivo and may be a potent adjuvant by providing inflammatory signals which 
may optimize adequate antigen presentation. Indeed, most if not all, classical 
adjuvant substances promote local inflammation. However, the stimulation of 
excessive systemic inflammatory responses seems undesirable for an immune 
adjuvant. Although the number of patients treated at doses other than 0.5 J.Lg/kg 
of Il-12 is, due to the original phase I design of the study, rather small, our 
results may give an indication of the dose of rHuiL-12 to be used as immune 
adjuvant in humans. At s.c. doses of 0.5 and 1.0 J.Lg/kg, rHuiL-12 is a strong 
stimulator of systemic inflammatory mediator systems. However, after a dose of 
0.1 J.Lg/kg rHuiL-12, i.e. one fifth of the maximum tolerated dose, the systemic 
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inflammatory responses were only limited. Previously we have shown that at a 
dose of 0.5 f!gfkg IL-12 induces activation of fibrinolysis and coagulation in 
humans [Portielje et al, 2001]. These side effects may have contributed to the 
hemorrhagic events, which complicated administration of IL-12 in other clinical 
phase I and II studies [Atkins et al, 1997; Motzer et al, 1998; Leonard et al, 
1997]. In view of our current results that at 0.1 f!g/kg rHuiL-12, PMN are 
activated, whilst only small amounts of systemic sPLA2 are formed and activation 
of fibrinolysis is minimal, in the absence of activation of the coagulative 
response, we suggest that IL-12 as an adjuvant should not be used at doses 
higher than 0.1 f!g per kg in order to prevent serious systemic inflammatory 
responses. 
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Abstract 
The clinical development of interleukin 12 (IL-12) as a single agent for 
systemic cancer therapy has been hindered by significant toxicity and 
disappointing anti-tumor effects. The lack of efficacy was accompanied by, and 
probably related to, declining biological effects of IL-12 in the course of repeated 
administrations at doses approaching the maximum tolerated dose (MTD). 
Nevertheless, IL-12 remains a very promising immunotherapeutic agent because 
recent cancer vaccination studies in animal models and humans have 
demonstrated its powerful adjuvant properties. Therefore, IL-12 may re-enter 
the arena of cancer therapy. 
Here we review the immune modulating characteristics of IL-12 considered 
responsible for the adjuvant effects, as well as the results of animal and human 
cancer vaccination studies with IL-12 applied as an adjuvant. In addition, we 
discuss how studies with systemic IL-12 in cancer patients, and several other 
lines of evidence indicate that IL-12 may exert optimal adjuvant effects only at 
low dose levels. Therefore, the MTD may not constitute the maximum effective 
dose of IL-12 for adjuvant application. 
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Introduction 
Specific immunity against cancer, if present, is usually not effective, as 
shown by the course of most human cancers. Therefore, the discovery of tumor 
associated antigens for an increasing number of human malignancies [Boon et al, 
1997; Rosenberg et al, 1999], has raised expectations of effective vaccination 
therapy of cancer, with the goal to induce immunity against cancer. Apparently, 
an effective immune response is not elicited by the tumor antigens that are 
expressed by cancers that have become clinically manifest. Indeed, in animal 
models, antigenic tumor cells have been shown to grow in immune-competent 
hosts without stimulating an acute or memory T cell response [Wicket al, 1997; 
Speiser et al, 1997]. An important role in the ineffective immune responses to 
cancer is thought to be played by the mechanism of immune tolerance. Some 
tumors are capable of in vitro tolerance induction in T lymphocytes that are 
specific for their tumor antigens [Staveley-O'Carroll et al, 1998]. The reversal of 
immune tolerance into immune activation may be one of the mechanisms by 
which cancer vaccination can become an effective treatment modality. 
Among the strategies to stimulate an effective immune response against 
tumor antigens is the presentation of antigens together with an appropriate 
immune adjuvant. Recently, Il-12 has been identified as a powerful adjuvant 
substance in a variety of vaccination models of infectious disease. Promising 
results have also been obtained in animal cancer vaccination studies using either 
local or systemic co-administration of Il-12, or Il-12 gene-transduced cellular 
vaccines. The first results in humans clearly demonstrate that IL-12 enhances 
tumor specific cellular responses [Lee et al, 2001; Gajewski et al 2001]. IL-12 
has several characteristics that seem essential for its adjuvant effects. In the 
vaccination area, IL-12 activates innate immune cells and promotes production 
of cytokines and chemokines, thereby mediating the attraction of other innate as 
well as specific immune cells to this region. We hypothesize that the co-
administration of tumor antigens together with the strong pro-inflammatory 
cytokine IL-12, provides the environment with inflammatory danger signals 
required to activate antigen presenting dendritic cells (DC) and prevents 
tolerance induction towards the tumor antigens. In addition, IL-12 directs the 
development ofT-helper lymphocytes towards the type 1 (Th1) functional profile 
that promotes cellular immune responses, and stimulates the proliferation of 
antigen specific cytotoxic T lymphocytes (CTL) and thereby establishment of 
immune memory. 
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The beneficial adjuvant properties of IL-12 that were demonstrated in 
infectious disease models [Gherardi et al, 2001], may not apply to tumor 
immunology. Various theoretical models of immune activation share the view, 
that tumor cells and infectious pathogens are differently recognized by the 
immune system. The "danger model" hypothesizes that specific immune 
activation, as opposed to tolerance, is initiated when innate immune cells 
recognize danger signals [Matzinger et al, 2001]. Invasion of pathogens is 
usually accompanied by local inflammation and tissue destruction, resulting in 
danger signals and activation of antigen presenting cells (APC) which then 
provide co-stimulatory signals to initiate specific immune responses. In contrast, 
when tumor antigens arise during malignant transformation, tissue destruction is 
initially minimal. The consequent absence of adequate danger signals is thought 
to result in immune tolerance towards the antigen. The "innate immune 
recognition model" assumes that specific immune responses are only activated 
when innate immune cells recognize conserved microbial structures with their 
pattern recognition receptors (PRR) [Medzhitov et al, 2000]. Once the PRR 
identify a pathogen-associated molecular pattern, the innate immune cells are 
triggered to perform their effector functions and activate specific immune cells. 
Tumor cells are unable to activate PRR, and hence do not trigger innate immune 
cells to activate specific immune cells. Because of these essential differences 
between the immune recognition of tumor cells and infectious pathogens, the 
present discussion is restricted to results obtained in experimental tumor models 
and cancer patients. 
Molecular structure, production and cellular receptors 
Interleukin 12 is composed of two disulfide-linked sub-units with molecular 
weights of 40kDa (p40) and 35kDa (p35) [Kobayashi et al, 1989; Podlaski et al, 
1992]. The human p35 and p40 sub-units are structurally unrelated and have 
been mapped to chromosomes 3p12-3q13.2 and Sq31-q33 respectively 
[Sieburth et al, 1992]. Cells require co-expression of both genes to secrete 
biologically active IL-12 [Wolf et al, 1991]. IL-12 is primarily produced by 
phagocytic cells and antigen presenting cells (APC) such as monocytes, DC and 
activated B lymphocytes [Trinchieri et al, 1998; Heufler et al, 1996; Schultze et 
al, 1999], and production is strongly stimulated by infectious pathogens and 
their products [D'Andrea et al, 1992; Sato et al, 1996]. The other important 
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stimulus for IL-12 synthesis are interactions between CD40 and its ligand 
(CD154), on B cells or T cells and APC, respectively [Shu et al, 1995]. 
Natural killer- (NK) and T cells were first shown to express high affinity 
receptors for IL-12 composed of two sub-units, designated ~1 and ~2 [Presky et 
al, 1996]. Subsequently, several other cell types, such as neutrophils, DC, B 
lymphocytes and eosinophils, were shown to respond to IL-12 in vitro [Desai et 
al, 1992; Nutku et al, 2001; Nagayama et al, 2000; Vogel et al, 1996; Bussolati 
et al, 1998; Bryan et al, 2000; Airoldi et al, 2000]. Signal transduction through 
the high affinity receptors on lymphocytes involves tyrosine phosphorylation of 
the Tyk2 and Jak2 kinases and of the transcription factors STAT3 and STAT4 
[Bacon et al, 1995a; Bacon et al, 1995b; Jacobson et al, 1995]. 
Clinical studies of systemic Il-12 as a single therapeutic anti-
tumor agent 
Recombinant human IL-12 has been studied as a single agent for systemic 
treatment in patients with various types of cancer. The development of IL-12 has 
proceeded along usual, FDA required lines, with initial phase I studies to 
determine tolerability and safety [Atkins et al, 1997; Motzer et al, 1998; Portielje 
et al, 1999; Gollob et al, 2000, Ohno et al, 2000] and subsequent efficacy 
studies [Leonard et al, 1997;Motzer et al, 2001; Hurteau et al, 2001]. The 
maximum tolerated dose (MTD) of IL-12, i.e., one dose level below the dose that 
caused dose limiting toxicity, was defined between 200 and 500 ng/kg, 
in several intravenous (i.v.) and subcutaneous (s.c.) schedules consisting of 3 to 
6 injections per 3 weeks. Common side effects consisted of fever and flu like 
symptoms, nausea, fatigue, mucositis and elevation of liver enzymes. IL-12 
appeared to have an exceptionally long elimination half life, estimated between 9 
to 25 hours, in comparison with other cytokines, [Portielje et al, 1999; Atkins et 
al, 1997; Motzer et al, 1998; Bajetta et al, 1998; Ohno et al, 2000]. A 
remarkable decrease of the area under the plasma concentration time curve 
(AUC) occurred after repeated injections of IL-12 [Portielje et al, 1999; Rakhit et 
al, 1999; Bajetta et al, 1998]. This reduction in AUC was possibly due to up-
regulation of IL-12 receptors on lymphocytes in the course of treatment, in 
accordance with results obtained in a mouse model, and unrelated to anti-IL-12 
antibody production [Thibodeaux et al, 1999]. 
The first phase II study unexpectedly resulted in severe toxicity and deaths. 
IL-12 was administered at the MTD defined in a previous phase I study [Atkins et 
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al, 1997], and the schedule was identical except for the omission of a treatment 
free period after the first dose [leonard et al, 1997; Cohen, 1995]. Subsequent 
animal studies revealed that insertion of a treatment free period of a week after 
the first administration of Il-12, conform most phase I studies, reduced the 
toxicity of subsequent injections [leonard et al, 1997; Sacco et al, 1997]. 
Moreover, these phase I studies also revealed that the reduction of side effects 
that occurred upon repeated injections [Portielje et al, 1999; Motzer et al, 1998] 
was accompanied by reduced IFN-y induction [Sacco et al, 1997; leonard et al, 
1997; Bajetta et al, 1998; Portielje et al, 2002a; Rakhit et al, 1999; Gollob et al, 
2000; Atkins et al, 1997]. In vitro, decreased IFN-y secretion by T cells was 
related to cellular depletion of the signaling component STAT4 after prolonged 
Il-12 stimulation [Wang et al, 2001]. Since IFN-y is considered to be the key 
regulator of Il-12 mediated anti-tumor effects, the down-regulation of its 
induction in the course of Il-12 treatment raised concerns [Brunda et al, 1995a; 
Nastala et al, 1994; Fujiwara et al, 1997;. In addition, our group showed that the 
down-regulation of biological effects also comprises the induction of TN F-a, Il-8 
and ll-6 and the effect on leukocyte subset counts in the circulation. The 
concentrations of ll-10 remained elevated upon repeated Il-12 administrations 
[Portielje et al, 2002a; Bajetta et al, 1998; Ohno et al, 2000; Motzer et al, 
2001]. It has been hypothesized that Il-10, as an endogenous counter regulator 
of many ll-12 mediated effects, is produced during ll-12 therapy to protect the 
body from the resultant ongoing and damaging inflammatory activity [Meyaard 
et al, 1996]. This hypothesis was supported by in vitro results demonstrating ll-
12 to induce high levels of inhibitory ll-10 production by lymphocytes [Gerosa et 
al, 1996; Windhagen et al, 1996]. The results of Phase II studies, performed in 
patients with advanced renal cell and ovarian cancer, were disappointing, with 
overall response rates of only 7% and 4%, respectively [Motzer et al, 2001; 
Hurteau et al, 2001]. The lack of efficacy in these studies may be due to down-
regulation of biological effects, including potential anti-tumor effects, due to 
endogenous Il-10 induction, that occurs at relatively high dose levels of Il-12. 
In the development of Il-12 as a vaccine adjuvant, strategies that do not 
result in long-term systemic exposure to high concentrations of Il-12, such as 
administration of low doses or infrequent administrations, may therefore be 
necessary to prevent down-regulation of effects. 
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Properties of Il-12 that can mediate adjuvant effects 
Effects on the innate immune svstem 
Inflammation 
As a strong pro-inflammatory cytokine, IL-12 induces the production of 
multiple other cytokines. Although the induction of IFN-y predominates, it also 
enhances production of other pro-inflammatory cytokines such as GM-CSF, TNF-
a, IL-8, IL-6, IL-15 and IL-18 in humans [Portielje et al, 2002a; Ohno et al, 
2000; Gollob et al, 2000]. Importantly, IFN-y operates in a positive feedback 
mechanism, as IFN-y in turn stimulates IL-12 synthesis by phagocytic cells 
[Cassatella et al, 1995]. In accordance with previous results in non-human 
primates [Lauw et al, 1999], we have shown activation of multiple inflammatory 
mediator systems in patients with advanced renal cell cancer after s.c. IL-12 
[Portielje et al, 2002b]. 
In vitro, binding of IL-12 to receptors on neutrophils results in activation of 
Ca2+ and tyrosine signaling pathways [Collison et al, 1998]. We also observed 
activation and degranulation of neutrophils in humans. The activation of 
neutrophils might be a prominent adjuvant property of IL-12, as neutrophils can 
operate as intermediates between innate and adaptive immunity, not only 
responding to cytokines, but also producing cytokines and chemokines that 
enable the attraction of other immune effector cells [Colombo et al, 1992; Ethuin 
et al, 2001]. For example, platelet activating factor, released from human 
neutrophils in response to IL-12, attracts other neutrophils and NK cells via 
chemotaxis [Bussolati et al, 1998]. The potentially important role played by 
neutrophils in cancer immune surveillance was demonstrated with tumor cells 
engineered to produce pro-inflammatory cytokines, such as IFN-y and TNF-a. 
Vaccination with these cells resulted in anti-tumor immunity against wild-type 
parental tumor depending on neutrophils and CTL [Musiani et al, 1996]. 
Another inflammatory effect observed in humans after IL-12 administration, 
was an increase in serum concentrations of secretory phospholipase A2 (sPLA2) 
[Portielje et al, 2002b]. Secretory phospholipase A2 may be released from 
endothelial cells in response to IL-12 mediated TNF-a and IL-6 synthesis, both 
known pro motors of sPLA2 production. This lipolytic enzyme releases fatty acids, 
often arachidonic acid, from membrane phospholipids [Crowl et al, 1991]. These 
are considered strong mediators of the inflammatory response. 
Fibrinolysis and coagulation were also activated by IL-12 in humans [Portielje et 
al, 2001]. The coagulation system is integrally related to the innate immune 
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response and its activation promotes other inflammatory responses [Opal, 
2000]. Thrombin formation occurred in 50% of patients after IL-12. Thrombin 
induces up-regulation of P-selectin and E-selectin; as a result aggregation of 
platelets with neutrophils, and interactions of neutrophils and monocytes with 
endothelial cells are promoted [Drake et al 1992; An rather et al, 1997]. 
In conclusion, the pro-inflammatory properties of IL-12 can mediate 
activation and attraction of innate immune cells, resulting in the recruitment of 
specific immune cells. 
ll-12 may also promote immune activation against tumor antigens because 
the activation of multiple inflammatory systems results in danger signals 
[Matzinger, 2001]. IL-12 production by phagocytic cells and APC is an early 
event shared by a variety of pathological states that evoke activation of the 
innate and, subsequently, antigen-specific immune responses [Sousa et al, 
1997]. During sepsis and endotoxemia, IL-12 is produced [Heinzel et al, 1994; 
Jansen et al, 1996; Hazelzet et al, 1997], and the inflammatory response in 
these situations seems dependent on ll-12, as neutralizing antibodies against IL-
12 can arrest the inflammatory cascade following bacterial lipopolysacharide 
administration [Wysocka et al, 1995]. Therefore, we propose, that co-
administration of ll-12 and tumor antigens results in a local inflammatory 
response, with release of neutrophil elastase and other proteases, and synthesis 
of thrombin and lipid mediators, resulting in micro environmental damage 
[Weiss, 1989; Okrent et al, 1990; Kuipers et al, 1994]. This provides danger 
signals required for immune activation. As a result, local APC are activated, and 
can provide co-stimulatory signals and activate T cells. 
Notably, stimulation of Il-12 production is also considered an important 
working mechanism in vaccination, whereby classical adjuvant substances exert 
their effects. This was shown for example for immune stimulating complexes 
containing saponin Quil A, and nucleic acid vaccines containing unmethylated 
CpG tracts [Smith et al, 1999; Sate et al, 1996; Chace et al, 1997]. 
Natural killer cells 
NK lymphocytes are also activated by IL-12, in fact, it was initially 
discovered in 1989 as NK cell stimulatory factor [Kobayashi et al, 1989]. IL-12 
promotes NK cell cytotoxicity, cytokine production, in particular high levels of 
IFN-y [Aste-Amegaza et al, 1994; Naume et al, 1992; Robertson et al, 1992], 
and mediates NK cell chemotaxis [AIIavena et al, 1994; Fogler et al, 1998]. In 
cancer patients, ll-12 indeed enhances the cytolytic activity of NK cells and 
increases the expression of C02, LFA-1 and CD56 molecules, that mediate NK 
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cell migration [Robertson et al, 1999]. In a mice leishmania infection model, NK 
cells were shown to exert an intermediate function between the innate and 
specific immune responses. The strong Th1 response, obtained after 
administration of leishmania/ antigens in combination with ll-12 to mice, 
depended on NK cells and could be completely abrogated by in vivo depletion of 
NK cells [Afonso et al, 1994]. NK cells also have direct cytotoxic effects against 
MHC class 1 deficient tumors [Trinchieri, 1989]. Tumor eradication after 
vaccinations supported by adjuvant IL-12 is dependent on NK cells in several 
animal models [Jyothi et al, 2000; Smyth et al, 2001; Kodama et al, 1999]. In 
this context it is of interest that IL-12 deficient mice are more sensitive to 
chemical carcinogens and develop increased numbers of metastases following 
injection of transplantable tumor, as compared to wild-type controls, and that 
this immune surveillance defect is related to sub-optimal NK-cell function [Smyth 
et al, 2000]. 
Dendritic cells 
Moreover, IL-12 enhances the function of DC, which are professional APC 
capable to process antigen in the setting of vaccination, as they provide high 
concentrations of peptide /MHC ligands forT cell receptor engagement, required 
to activate specific immunity. DC express IL-12 receptors, and their occupation 
initiates nuclear localization of members of the NF-KB family of transcription 
factors [Grohmann et al, 1998]. They are supposed to increase the maturation of 
be and enhance their capability to present antigen [Pettit et al, 1997], e.g., by 
up-regulation of class II MHC expression [Grohmann et al, 2000]. Furthermore, 
IL-12 promotes the differentiation and maturation of DC indirectly, via the 
induction of pro-inflammatory cytokines. The pro-inflammatory cytokines TNF-a, 
Il-6, and GM-CSF have been shown to mediate migration of DC to T-cell rich 
areas of lymphoid organs in order to form clusters with antigen-specific T cells, 
creating the appropriate environment for T helper cell differentiation [Austyn, 
1996; Jonuleit et al, 1997]. In addition, IFN")' enhances antigen processing by 
DC and their MHC class !-presentation of antigen [Brossart et al, 1997; Fruh et 
al, 1999]. 
In recent years, DC based vaccines have received intense interest [Reid, 
1998]. DC can be generated in vitro [Young, 1999] and loaded with tumor cell 
lysates or tumor peptides before administration to the patient. In this way the 
physiological process that recruits antigen specific T cells is mimicked to some 
degree. Although mature DC themselves are potent producers of IL-12, co-
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administration of Il-12 improves the results of DC based vaccines. In vitro, CTL 
responses, triggered by autologous human monocyte-derived DC that were 
modified to express melanoma antigens, could be enhanced by co-transfecting 
these DC with IL-12 genes [TOting et al, 1998]. In situations where antigen 
presentation by DC without IL-12 co-administration induced T cell anergy, IL-12 
could reverse or prevent development of tolerance in favor of immune activation 
[Grohmann et al, 1997]. Similarly, IL-12 was shown to be able to convert DC 
from a state of tolerance to activity. In patients that presented simultaneously 
with progressing and regressing metastases, tissue DC from progressing 
metastases appeared unable to induce T cell proliferation and did not produce 
Th1 cytokines, in contrast to DC from regressing metastases, and this defect 
could be overcome by Il-12 addition [Enk et al, 1997]. 
In conclusion, IL-12 plays an important role in the activation of innate 
immunity and potentially provides tumor antigens with a background of 
inflammatory effects with resultant "danger" signals that can promote activation 
of specific immunity. 
Effects on specific immune cells 
Cellular immune response 
The cytokines present in the micro-environment at the time of initial antigen 
stimulation direct the differentiation of naive T cells into effector T cell subsets. 
MHC-restricted, Ag-specific T lymphocytes are considered to be an important 
effector mechanism against cancer. 
In the presence of IL-12 naive T cells differentiate into the functionally 
defined Th1 subset [Hsieh et al, 1993] that is involved in cell mediated 
immunity. Subsequently, IL-12 is an important co-stimulus for proliferation and 
further activation of fully differentiated Th1 cells and their secretion of IFN-y 
[Manetti et al, 1993; Germann et al, 1993]. 
T lymphocytes respond to IL-12 through high affinity receptors, which are 
composed of two sub-units, termed ~1 and ~2 [Presky et al, 1996]. Th1 cells 
express both sub-units. However, if T helper cells differentiate along the Th2 
pathway, supporting humoral immune responses, they selectively lose IL-12R~2 
and thereby become unresponsive to IL-12 [Szabo et al, 1997]. Th1 commitment 
is enhanced by IFN-y, which further up-regulates the IL-12 receptor [O'Garra, 
1998; Trinchieri, 1996]. Once a Th1 response is induced in vivo, Il-12 is in most 
cases not necessary for maintaining this response [Gazzinelli et al, 1994]. This 
observation is important for vaccination strategies, as it implies that addition of 
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IL-12 to the vaccine only would be sufficient to induce and maintain the desired 
response. 
In addition, IL-12 modulates a number of genes involved in Th1 trafficking 
and regulates the migration and homing of these cells. IL-12 can attract and 
maintain Th1 cells to the site of administration by the up-regulation of Th1 
specific adhesion molecules and their ligands. For example, IL-12 selectively 
increases the expression of integrin-0<6/~1 and chemokine receptor CCR1 on Th1 
cells in vitro [Colantonio et al, 1999]. Also, IL-12 upregulates the expression of 
glucosyltransferase enzymes that increase the expression of P-selectin and E 
selectin ligand on Th1 cells which enables their recruitment to inflamed tissues 
[White et al, 2001]. Finally, IL-12 strongly induces the expression of IP-10 in 
various cell types in vitro [Sgadari et al, 1996]. IP-10 is the ligand of chemokine 
receptor CXCR3, selectively expressed on Th1 cells [Mantovani, 1999]. In 
accordance, peripheral blood mononuclear cells [PBMC) and tumor biopsies from 
cancer patients showed increased expression of IP-10 after IL-12 treatment 
[Haicheur et al, 2000; Bukowski et al, 1999]. 
DC play an essential intermediate function in the facilitating interaction 
between T helper cells and antigen specific cytotoxic CDS+ T lymphocytes (CTL). 
Priming of CTL is enabled by the ligation of CD40 on DC and its ligand CD154 on 
activated CD4+ cells [Schoenberger et al, 199S; Bennett et al, 199S]. The strong 
induction of IL-12 synthesis that occurs as a result of CD40 ligation, suggests an 
important role for IL-12 in the molecular mechanisms responsible for the CTL 
priming. This contention is further supported by studies using latex microspheres 
coated with various combinations of class I MHC-peptide complexes and co-
stimulatory molecules, thus avoiding the use of APCs whose function may be 
affected by cytokines. It was hence shown that IL-12, in the presence of antigen, 
acts directly on the naive CDS+ CTL to promote clonal expansion and 
differentiation [Curtsinger et al, 1999]. 
That IL-12 plays an important role in the establishment of immunological 
memory was demonstrated in an experimental system, in which a small number 
of antigen-specific CDS+ CTL were adoptively transferred into naive, syngeneic 
mice, in order to monitor responses to peptide immunization in the absence or 
presence of IL-12. Peptide immunization without simultaneous IL-12 
administration induced a weak and transient expansion of CDS+ CTL, whereas in 
the presence of IL-12, a large clonal expansion of CDS+ T cells was induced in 
the draining lymph nodes. These cells were capable of antigen specific killing in 
in vitro assays. Additionally, a stable memory T cell population was generated 
that responded to a second challenge with IL-12 and peptide [Schmidt et al, 
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1999]. A strong specific CTL response was observed in patients with advanced 
melanoma after administration of IL-12. Numbers of tumor specific CTL 
increased in the circulation and influx of specific memory CDS+ T cells into 
metastasized lesions was documented [Mortarini et al, 2000]. 
Humoral immune response 
With respect to humoral immunity, addition of IL-12 to protein and hapten 
vaccinations strongly up-regulates the synthesis of Ag-specific, complement 
fixing IgG2a, IgG2b and IgG3 antibody subclasses [Germann et al, 1995; 
Buchanan et al, 1995]. Further experiments in mice revealed that the elevation 
of these antibody isotypes is dependent on IFN-y induction [Metzger et al, 1997]. 
However, in IFN-y knock-out mice, IL-12 still significantly enhances the synthesis 
of specific IgG1 and IgG2b. Therefore a two step model of humoral immune 
enhancement by IL-12 was proposed [Metzger et al, 1997]. Initially, the IL-12 
induced production of IFN-y by Th1 and NK cells, would mediate early switching 
of B cells towards IgG2 immunoglobulin secretion with temporal suppression of 
IgG1 production. Subsequently, IL-12 would stimulate the switched B cells to 
secrete increased amounts of antibody, regardless of their isotype [Metzger et al, 
1996]. 
IL-12 was also identified as a pivotal molecule secreted by activated human 
DC that promote the differentiation of naive B cells into IgM secreting plasma 
cells and hence plays an important role in generation of primary antibody 
responses that are initiated by DC [Dubois et al, 1998]. Finally, IL-12 may exert 
indirect effects on B cells via the induction of other cytokines than IFN-y. We 
have shown in patients with renal cell cancer, that IL-12 induces elevation of 
serum levels of IL-6 [Portielje et al, 2002a], which is a prominent stimulator of B 
cell differentiation and immunoglobulin synthesis [Van Snick, 1990]. 
Adjuvant effects of Il-12 in animal studies 
The addition of IL-12 to different types of cancer vaccines has been 
extensively studied in animal (mostly murine-) models. The first vaccination 
protocol addressed the co-administration of IL-12 with tumor derived peptide 
and resulted in the induction of peptide specific CTL in naive, tumor bearing mice 
and the eradication of established tumors [Noguchi et al, 1995]. Several studies 
used cancer cells as vaccines, that had been transduced to express IL-12 [Tahara 
et al, 1995 and 1996; Rodolfo et al, 1996; Fallarino et al, 1997 and 1999; 
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Schmitt et al, 1997; Cavallo et al, 1997; Chen et al, 1997; Popovic et al, 1998; 
Hoshino et al, 1998, Lode et al, 1998, Myers et al, 1998; Fuji et al, 1999; 
Dunussi-Joannopoulos et al, 1999; Carr-Brendel et al, 1999; Adris et al, 2000; 
Lechanteur et al, 2000, Nagai et al, 2000]. Alternative approaches also resulted 
in the presence of Il-12 at the site of tumor antigen. Recombinant viral vectors, 
encoding Il-12 [Bramson et al, 1996] Caruso et al, 1996; Puissieux et al, 1998; 
Rakhmilevich et al, 1997; Fernandez et al, 1999], or fibroblasts, transfected for 
Il-12 production, were injected near the tumor [Tahara et al, 1994; Matsumoto 
et al, 1999]. More recently, studies have applied co-administration of genes 
encoding for Il-12 and various tumor antigens [Tan et al, 1999; Amici et al, 
2000; Song et al, 2000; Kim et al, 2001]. The addition of Il-12 to these vaccines 
clearly enhanced the anti-tumor effects, with resultant inhibition of tumor growth 
and eradication of established tumors. Additionally, immune memory was 
established with rejection of tumor cells at a subsequent challenge. In several 
studies, separate analyses have demonstrated that ll-12 plus vaccine was more 
effective than either component alone [Pulaski et al, 2000; Rodolfo et al, 1996; 
Lechanteur et al, 2000; Fuji et al, 1999; Hoshino et al, 1998; Jean et al, 1998; 
Adris et al, 2000; Cavallo et al, 1997; Dunussi-Joannopoulos et al, 1999; 
Fallarino et al, 1997 and 1999]. In vivo depletion of cellular subsets [Adris et al, 
2000; Dunussi-Joannopoulos et al, 1999; Lode et al, 1998; Musiani et al, 1996; 
Pulaski et al, 2000; Weber et al, 1999; Puisieux et al, 1998] and knockout mice 
[Hunter et al, 1997; Puisieux et al, 1998; Song et al, 2000] have been used to 
investigate the anti-tumor mechanism of IL-12. Additionally, the cellular infiltrate 
in tumor metastases after vaccination has been characterized [Hunter et al, 
1997; Fernandez et al, 1999; Nanni et al, 2001]. In most studies, lymphocytes 
were pivotal effector cells. The lymphocyte subsets involved, such as CD 8+ T 
cells, CD4+ T cells, NK cells or a combination of these, varied with the specific 
vaccine and the tumor model studied. Infrequently, other immune effector cells 
such as macrophages have been implicated in the anti-tumor effects of ll-12 
[Tsung et al, 1997]. Additionally, 11-12 was shown to stimulate humoral 
immunity. In a model of colon carcinoma, vaccination with Il-12 transduced 
tumor cells cured 40°/o of tumor bearing mice. Favorable anti-tumor responses 
were related to the synthesis of antibodies against tumor associated antigens 
that induced tumor cell lysis in a complement dependent cytotoxicity assay 
[Rodolfo et al, 1996]. Moreover, ll-12 increased anti-neu antibody synthesis, in 
a model in HER-2/neu transgenic mice. Although antibody levels were not 
correlated with anti-tumor protection, vaccination with a combination of plasm ids 
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encoding the neu oncogene and IL-12, resulted in protection against mammary 
tumors that normally develop spontaneously in these mice [Amici et al, 2000]. 
In several recent studies IL-12 has been combined with other strategies 
aimed to promote effective immune responses against tumor antigens. The 
administration was systemically, together with tumor cells transduced to express 
co-stimulatory molecules such as B7-1 or MHC class II [Joki et al, 1999; Pulaski 
et al, 2000]. An important and promising vaccination strategy consists of the 
addition of Il-12 to DC based vaccines [Melero et al, 1999; Zitvogel et al, 1996; 
Fallarino et al, 1999; Koido et al, 2000]. In a mouse model of chemically induced 
fibrosarcoma, DC were pulsed with tumor peptides, that had been eluted with 
acid from autologous tumor [Zitvogel et al, 1996]. These DC were combined with 
intra-peritoneal administration of Il-12. Alternatively, antigen-loaded DC were 
transfected with a retroviral vector or a pro-viral construct encoding murine riL-
12. Both strategies augmented the anti-tumor effect of the vaccine, enhanced 
the growth arrest of established tumors and increased specific cytotoxicity of 
splenic T cells, as compared to treatment with non-transfected, peptide pulsed 
DC or ll-12 alone. A recent experiment with DC in MHC-1 transgenic mice 
demonstrated that Il-12 can even reverse tolerance in vivo. MUC1 is over-
expressed in human breast and other cancers. Administration of MUC-1 
expressing DC to the MUC-1-transgenic mice only elicited a specific anti-MUC 
immune response, if ll-12 was co-administered along with the DC [Koido et al, 
2000]. MUC-1-specific CTL were also induced when antigen pulsed PBMC, instead 
of DC, served as APC. Because peptide-loaded autologous human PBMC can be 
obtained relatively easy, in contrast to DC, this is an attractive approach to 
translate for clinical use and indeed, similar studies are now performed in 
humans. 
Adjuvant effects of Il-12 in human studies 
Clinical experience in humans is still limited. Results of two studies with 
tumor peptide vaccination and Il-12 co-administration in patients with malignant 
melanoma were recently published [Gajewski et al, 2001; lee et al, 2001]. One 
study was performed in patients with metastasized melanoma/ using a vaccine 
consisting of autologous PBMC pulsed with MAGE-3 or MelanA peptides and co-
administration of recombinant Il-12 [Gajewski et al, 2001]. Fifteen HLA-A2 
positive patients with metastases expressing MAGE-3 or Melan-A, were 
vaccinated with these tumor peptides at least 3 times at three week intervals. 
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Different doses of IL-12 were used (0, 30, 100 or 300 ngjkg) and IL-12 was 
administered s.c., adjacent to the vaccination site, on days 1, 3 and 5. Only one 
out of four patients treated with pulsed PBMC without IL-12, but all patients 
treated with 30 or 100 ng/kg of IL-12 developed a specific CDS+ T cells response 
after 3 immunizations. Remarkably, only one out of three patients treated at the 
highest dose level of 300 ng/kg of IL-12 did so. Furthermore, grade 2 or 3 
toxicity (fatigue, depression and decreased numbers of peripheral blood cells) 
only occurred with the highest dose of IL-12. Most importantly, 6 of S patients 
with tumor-specific CDS+ T cells showed regression of all, or part of their 
metastases. In the second study, patients with stage III or IV malignant 
melanoma/ who had undergone complete resection of macroscopic tumor, were 
vaccinated with peptides derived from the tumor antigens gp100 and tyrosinase, 
emulsified with incomplete Freund's adjuvant [Lee et al, 2001]. Patients 
received, during 26 weeks, a total of S vaccinations, with or without 30 ng /kg 
IL-12. The combination augmented gp 100-specific DTH reactivity and boosted 
the gp100- and tyrosinase specific production of IFN-y by peripheral blood T cells 
after repeated vaccinations. The number of gp100 specific CTL as measured by 
tetramer flow cytometry was also augmented by IL-12. Of note, the generation 
of specific CTL responses took several vaccinations over multiple months. This 
observation confirmed the clinical impression that patients with rapidly 
progressive disease may not benefit from therapeutic vaccination. Time to 
relapse was not influenced by the addition of IL-12 to the regimen, and did not 
correlate with any of the immunological results. In a third study, the treatment 
of 6 patients with advanced melanoma with weekly vaccinations, using IL-12 
gene-transfected autologous irradiated tumor cells, resulted in one mixed 
response (disappearance of part of the metastases). Two of 6 patients had an 
increased specific CTL response, as measured 2 weeks after the third 
vaccination, one of whom had a mixed response the other stable disease [Meller 
et al, 2000]. In this study, lymphokine activated killer cell activity was induced in 
the majority of patients, but was not related to clinical outcome. In another 
clinical protocol, peritumoral injection of IL-12 transfected fibroblasts was shown 
feasible, and reduction of tumor masses near the injection site were observed 
[Kang et al, 2001]. 
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Inverse Dose response effect 
In a human study that bears similarities to the study by Lee, patients with 
advanced malignant melanoma were treated with a vaccine consisting of gp100 
melanoma tumor antigen in incomplete Freund's adjuvant [Rosenberg et al, 
1999]. The vaccine elicited the generation of anti-peptide and anti-tumor T cell 
precursors in the circulation, while 42°/o of patients exhibited objective tumor 
regression, but unfortunately without attaining a clinical response. In sharp 
contrast with results by Lee, co-administration of IL-12 reduced the number ofT 
cell precursors and anti-tumor responses were no longer observed. However, IL-
12 was administered i.v. at a relatively high dose level, i.e. 250 ng/kgjday, on 5 
consecutive days after each peptide vaccination. 
In analogy with clinical studies of systemic single agent IL-12 administration, 
the biological effects of IL-12 may be down-regulated at the higher dose levels. 
Additional lines of evidence indicate that IL-12 in the setting of vaccination 
studies, does not exerts optimal immune modulation at high dose levels, and 
that above a certain threshold level, the dose response relationship may revert 
[Noguchi et al, 1995; Jean et al, 1998; Kurzawa et al, 1998]. A very low dose of 
1 ng per day, eight times during 2 weeks, co-administered with a p53 tumor 
peptide vaccine, induced tumor rejection and CTL generation in a murine 
sarcoma model, whereas doses higher than 10 ng per day failed to do so 
[Noguchi). In a rat glioma model, vaccination with irradiated tumor cells in 
combination with subcutaneous IL-12, resulted in maximal tumor eradication and 
optimal protective immunity against repeated tumor challenge at the lowest 
applied dose of 1 ng of IL-12 per day, for 28 days [Jean et al, 1998]. In contrast, 
treatment with high doses of 250 ng per day, for 10 days, prevented the 
generation of tumor specific CTL induced by immunization with GM-CSF-
transfected tumor cells [Kurzawa et al, 1998]. A possible inhibitory role for IL-10 
has been suggested in a model of adoptive transfer of specific CTL in immuno-
deficient mice bearing autologous tumor. In these mice, tumor growth 
suppression by CTL increased after injection of 100 ng of IL-12 into the tumor, 
every 2 to 3 days, but not after higher doses of 1000 ng [Asselin-Paturel et al, 
2001]. In vitro, it was then shown, that high dose IL-12 stimulated, in addition 
to IFN-y-, the production of high levels of IL-10 from the tumor specific CTL, and 
furthermore, anti-IL-10 polyclonal antibodies could abrogate the inhibition of 
tumor cell lysis observed after high dose IL-12. Since IL-12 and IL-10 have 
opposite effects on the accessory function of DC and other APC [Koch et al, 
1996], dose finding studies for IL-12 as adjuvant in therapeutic anti-tumor 
104 • Chapter 6 • 
vaccination should focus on those dose levels that do not induce IL-10 
production. 
Conclusions 
IL-12 is a promising adjuvant for cancer vaccination and has the potential to 
activate an effective immunological response to cancer. Firstly, it has strong 
inflammatory properties, and causes the induction of other pro-inflammatory 
cytokines, degranulation of neutrophils, the formation of lipid mediators and 
activation of the coagulative and fibrinolytic systems, that together can provide 
an environment of multiple danger signals for tumor antigens1 suitable for the 
activation of professional APC. In addition, IL-12 directly and indirectly activates 
innate immune effector cells such as neutrophils and NK cells, and promotes 
their secretion of substances that alter the microenvironment and promote 
expression of adhesion molecules that mediate trafficking and homing of APC and 
specific immune cells. Moreover, IL-12 enhances the maturation and antigen 
presenting efficacy of DC and promotes T helper cell differentiation towards Th1 
type, necessary for cellular immune responses. Finally, it stimulates the 
differentiation and lytic capacity of antigen specific CTL and promotes immune 
memory. 
The strong adjuvant properties of IL-12 have been demonstrated in a variety 
of animal models using different vaccination strategies that united tumor 
antigens and IL-12. Sophisticated vaccines have been constructed with antigen 
pulsed DC or PBMC, transduced to express increased IL-12. In these animal 
cancer models, IL-12 was shown to clearly enhance eradication of established 
tumor and moreover was capable of inducing a specific anti-tumor immune 
memory. The first human studies addressing the co-administration of systemic 
IL-12 to cancer vaccines have shown development of tumor-specific CTL in the 
course of multiple vaccinations and although clinical responses were limited, CTL 
responses were clearly correlated with clinical tumor regressions. Several lines of 
evidence indicate that the optimal immune regulatory effects of IL-12 are 
confined to the lower dose levels at which the induction of IL-10 does not take 
place. The maximally effective dose, schedule and route of administration remain 
to be defined. 
Based on the reviewed data, we anticipate the revival of IL-12 as adjuvant 
for therapeutic vaccination against cancer. 
Chapter 7 
Summary 
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The immunotherapy of cancer is based on the assumption that the immune 
system can be stimulated to recognize cancer and eradicate tumor. One of the 
approaches of immunotherapy consists of systemic administration of cytokines. 
Interleukin 12 (Il-12 ) is a cytokine with important immunoregulatory functions. 
The encouraging anti-tumor effects, observed in a variety of animal tumor 
models, have resulted in the development of Il-12 as a single agent for systemic 
cytokine therapy of cancer in humans. Renal cell cancer is one of the few human 
cancers that are more responsive to immunotherapy than to conventional 
cytotoxic therapies. 
We therefore performed a phase I and pharmacokinetic study of 
subcutaneously administered ll-12 in 28 patients with advanced renal cell cancer 
(chapter 1). Recombinant human Il-12 was administered on day 1, followed by 
an observation period of 7 days. Starting on day 8, repeated injections were 
administered 3 times a week, for two weeks. Dose limiting toxicity (DLT) of the 
initial injection was observed at 1.0 ~g/kg and consisted of fever, peri-vasculitis 
of the skin and leukopenia. DLT of the subsequent repeated injections was 
observed at 1.25 ~g/kg and comprised deterioration of performance status, 
fever, vomiting, mental depression and leukopenia. Other notable toxicity 
consisted of oral mucositis and elevation of hepatic enzymes. Fever, leukopenia 
and elevation of hepatic enzymes were more severe after the initial injection 
than after repeated injections at the same dose level. Peak levels of Il-12 were 
reached 9.7 hours after administration and the mean elimination half-life was 9.4 
hours, which is exceptionally long for a cytokine. At dose level 0.5 ~g/kg, the 
mean area under the plasma concentration-time curve (AUC) significantly 
decreased from 7.4 ng x h/ml after the first injection to 3.3 ng x h/ml after repe-
ated administrations, and at dose level 1.0 ~g/kg, from 32 ng x h/ml to 6.0 ng x 
h/ml, possibly due to upregulation of Il-12 receptors. It was concluded that the 
maximum tolerated dose (MTD) of the initial injection of rHull-12 was 0.5 ~g/kg, 
whereas the MTD of 3 subsequent administrations per week was, 1.0 ~g/kg. 
Upon repeated administrations of ll-12, side effects diminished. This 
prompted us to study whether or not the immunological effects decreased as well 
(chapter 3). Serial blood samples were collected from 26 patients in the course 
of the phase I study. The first injection of ll-12 was accompanied by rapid, 
transient and dose dependent increments of plasma levels of IFN-y, TN F-a, Il-10, 
Il-6, Il-8, but not Il-4. Additionally, rapid, transient, and dose dependent 
reductions of lymphocyte-, monocyte- and neutrophil counts were observed in 
the peripheral blood. The major lymphocyte subsets, i.e. CD 4+ and CDS+ T 
cells, B cells and NK cells, followed this pattern. Upon repeated injections, 
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concentrations of the inhibitory cytokine IL-10 further increased, while 
increments of plasma levels of IFN-y, TNF-a, IL-6 and IL-8, as well as 
fluctuations of leukocyte subset counts, were tapered. Dose escalation of IL-12 
within clinically tolerable margins did not reduce the decline of these 
immunological effects. Thus, upon repeated administrations of IL-12, levels of 
pro-inflammatory cytokines diminish, as well as effects on peripheral blood 
leukocyte subsets, while IL-10 production increases and may mediate the 
observed down-regulation of clinical and immunological effects. 
Several bleeding episodes that have been reported in the literature as a 
result of ll-12 administration to humans prompted us to study the effects of IL-
12 on fibrinolysis and coagulation (chapter 4). Coagulative and fibrinolytic 
responses were assessed in 18 patients with advanced renal cell carcinoma after 
subcutaneous administration of 0.5 !Lg/kg rHu!L-12. IL-12 induced sustained 
activation of fibrinolysis in the majority (94%) and substantial thrombin 
generation in half of patients. Plasmin-a2-antiplasmin complexes (PAPc) 
increased from 12 to a maximum of 19 nmol/1 at 72 hours. IL-12 induced the 
production of tissue plasminogen activator (tPA), whereas secretion of its natural 
inhibitor plasminogen-activator inhibitor-! (PAl) diminished. The elevation of tPA 
and reduction of PAl correlated with elevation of PAPc. Thrombin-anti-thrombin 
III complexes increased from 29 to a maximum of 460 ng/ml at 12 hours. The 
fibrinolytic response continued while thrombin generation had already abated 
and therefore occurred independently. Sequence and time frame of fibrinolytic 
and coagulative responses differ markedly from those observed after other 
cytokines and are not in agreement with an important mediator function of IFN-y 
or TN F-a. 
Studies in experimental animals and humans have shown that endogenously 
produced IL-12 plays an important role in the toxic sequel of sepsis and 
endotoxemia. In these situations, excessive activation of various components of 
the inflammatory cascade contributes to the development of tissue injury and 
mortality. We therefore studied the in-vivo effects of different doses of IL-12 on 
components of the inflammatory cascade (chapter 5). A single dose of 0.5 !Lg/kg 
IL-12 induced significant degranulation of neutrophils: plasma levels of elastase 
(azurophilic granules) and lactoferrin (specific granules) increased from 48 to 
117 ng/ml and from 124 to 181 ng/ml, respectively, at 24 hours. Additionally, 
IL-12 injection mediated the release of lipid mediators: Plasma concentrations of 
secretory phospholipase A2 (sPLA2) increased from 17 to 97 ng/ml. Systemic 
activation of inflammation by IL-12 occurred in a dose dependent way. At 0.1 
f!g/kg of IL-12, systemic responses were minimal: Although mild activation of 
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neutrophils was already detectable, formation of sPLA2 was limited. Because the 
hemostatic mechanism is tightly linked to the inflammatory cascade, it is 
important to note, that at this dose level, there was neither activation of the 
coagulative response and only minimal activation of fibrinolysis. 
While performing the studies presented in this thesis, reports of the first 
phase II studies of single agent systemic IL-12 in patients with advanced ovarian 
and renal cell cancer were published and demonstrated disappointing anti-tumor 
efficacy. In these studies, IL-12 was used at the MTD as defined in previous 
phase I studies, including the study described in chapter 2. Probably, the lack of 
efficacy is related to the decline of immunological effects of IL-12 that occurs in 
the course of repeated administrations at the MTD. Protective feedback 
mechanisms, such as the production of IL-10, may operate to abrogate the 
strong and potentially damaging systemic inflammatory responses that occur 
after relatively high dose IL-12. 
Recent cancer vaccination studies in animal models and humans have 
demonstrated that IL-12 has powerful adjuvant properties and hence remains a 
promising immunotherapeutic agent. All classical adjuvant substances are strong 
stimulators of local inflammation and therefore, the stimulation of inflammatory 
responses is thought to play an important role in the adjuvant effects of IL-12. In 
chapter 6, the adjuvant properties of IL-12 are reviewed. It is described how the 
pro-inflammatory effects of IL-12 can provide an environment of multiple danger 
signals for tumor antigens, resulting in activation of professional antigen 
presenting cells. Results of animal and human studies with IL-12 applied as an 
adjuvant for cancer vaccination are reviewed. Finally, it is discussed how clinical 
studies with systemic IL-12 and several other lines of evidence indicate that IL-
12 may exert optimal adjuvant effects only at low dose levels, and consequently, 
that the maximum tolerated dose is not be the most effective dose of !L-12. 
Final conclusions and future perspectives 
The initial administration of !L-12 to humans induces transient elevation of 
various other pro-inflammatory cytokines, and transient depletion of leukocytes 
in the peripheral blood. Upon repeated administration of !L-12, the induction of 
the inhibitory cytokine IL-10 is sustained, whereas the other immunological 
effects diminish. The disappointing anti-tumor effects observed in the first phase 
II studies are possibly related to this decline of biological effects. However, IL-12 
may re-enter the arena of cancer therapy, because recent cancer vaccination 
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studies have shown that IL-12 is a promising adjuvant substance, that seems to 
exert optimal effects at low dose levels. We hypothesize that localized 
inflammation plays a key role in the adjuvant effects of IL-12. On the other 
hand, administration of high dose IL-12 will trigger endogenous feedback 
mechanisms that annihilate the potential therapeutic effects. We anticipate 
therapeutic application of IL-12 as adjuvant for vaccination against cancer. 
Chapter 8 
Samenvatting 
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Het onderzoek dat wordt beschreven in dit proefschrift bestudeerde de klinische 
en biologische effecten van interleukine 12 (IL-12) bij patienten met 
niercelkanker. 
In Ieiding 
Niercelkanker is een relatief zeldzame ziekte. Patienten met deze vorm van 
kanker hebben in het algemeen een slechte prognose, omdat veel van hen bij 
presentatie van de ziekte al uitzaaiingen hebben. Helaas is uitgezaaide 
niercelkanker meestal niet geed te behandelen met chirurgie, radiotherapie of 
chemotherapie. Daarom wordt er veel onderzoek gedaan naar nieuwe manieren 
van behandeling. 
Het concept van immunotherapie bij kanker is gebaseerd op de 
veronderstelling dat het immuunsysteem kan worden gestimuleerd om kanker 
cellen te herkennen en te vernietigen. Eerder onderzoek heeft aangetoond dat 
niercel kanker een van de zeldzame kanker soorten is die relatief gevoelig is voor 
immunotherapie. Hoewel slechts een klein gedeelte van de patienten met 
uitgezaaide niercelkanker baat heeft bij de nu toegepaste vormen van 
immunotherapie, genezen sommige patienten uiteindelijk geheel. Dit resultaat 
motiveert onderzoek naar nieuwe immunotherapeutische behandelingen bij 
patienten met uitgezaaide niercelkanker. Een van de vormen van 
immunotherapie bestaat uit het toedienen van cytokines. Cytokines zijn in het 
lichaam natuurlijk voorkomende stoffen, die geproduceerd worden door 
verschillende cellen van het immuunsysteem en vervolgens de werking van 
andere immuuncellen sturen. In dierproeven werd aangetoond dat het cytokine 
IL-12 sterke anti-tumor effecten heeft. 
Het onderzoek 
Allereerst deden we een fase I onderzoek met IL-12 bij patienten met 
uitgezaaide niercelkanker (hoofdstuk 2). In fase I onderzoek wordt bepaald hoe 
een potentieel geneesmiddel door patienten wordt verdragen. Dit type onderzoek 
gaat vooraf aan fase II onderzoek, waarmee de uiteindelijke werkzaamheid bij 
een bepaalde ziekte wordt bepaald. Fase 1 onderzoek is niet erg geschikt om de 
werkzaamheid van potentiele geneesmiddelen te bepalen, omdat uiteindelijk 
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maar een klein aantal mensen met de meest effectieve dosis van het middel 
wordt behandeld. 
In ons onderzoek werd IL-12 met onderhuidse injecties, in een langzaam 
opklimmende dosering, aan kleine groepen patienten gegeven waarbij 
nauwkeurig werd bepaald wat de bijwerkingen bij de verschillende doseringen 
waren. Het onderzoek werd uitgevoerd in de Dr. Daniel den Hoed Kliniek, 
behorend tot het Erasmus Medisch Centrum in Rotterdam en in de Johannes 
Gutenberg Klinik, behorend tot de universiteit van Mainz in Duitsland. Met de 
studie werd bepaald welke de hoogste dosis is die kan worden toegediend zonder 
belangrijke bijwerkingen. Deze dosis was vervolgens de geadviseerde dosis voor 
fase II onderzoek dat in andere centra werd verricht. Frequente bijwerkingen van 
Il-12 waren: koorts, vermoeidheid, afname van de witte bloedcellen en 
verhoging van de leverenzymen in het bleed. In de loop van de behandeling kon 
de toegediende dosis Il-12 worden verhoogd, omdat de bijwerkingen afnamen 
en het middel dus beter werd verdragen. In onze studie werd slechts bij een van 
de 28 deelnemende patienten een tijdelijke afname van uitzaaiingen gezien en 7 
patienten had den tijdelijke stabilisatie van de ziekte. 
In fase I onderzoek wordt altijd de eerste ervaring met een middel bij 
patienten opgedaan. AI het onderzoek dat eraan vooraf is gegaan heeft zich in 
het algemeen in het laboratorium of in proefdieren afgespeeld. Tijdens fase I 
onderzoek wordt daarom ook altijd geprobeerd om zoveel mogelijk te weten te 
komen over de biologische effecten bij de mens. Wij waren ten eerste 
ge"interesseerd in de effecten die IL-12 bij patienten heeft op verschillende 
componenten van het immuunsysteem (hoofdstuk 3). De eerste IL-12 toediening 
gaf een verhoging van bloedspiegels van een hele reeks andere cytokines, terwijl 
de witte bloedcellen, die belangrijke functies vervullen bij de afweer, tijdelijk 
vanuit het bleed naar de organen trokken. Na de volgende Il-12 injecties bleef 
stijging van de meeste cytokines uit, evenals de effecten op de witte bloedcellen. 
Van een cytokine, namelijk IL-10, bleven de spiegels in de loop van volgende IL-
12 injecties wei stijgen. IL-10 wordt beschouwd als een remmer van het 
immuunsysteem, en de hoge spiegels hebben vermoedelijk de andere effecten 
van IL-12 onderdrukt. 
In een aantal studies, verricht door andere onderzoeksgroepen, waren na Il-
12 injectie ernstige bloedingen bij patienten opgetreden. Daarom bestudeerden 
we de effecten van IL-12 op de stalling (hoofdstuk 4). Nu bleek dat IL-12 injectie 
een langdurig stimulerend effect op de oplossing van bloedstolsels heeft, hetgeen 
bloedingsneiging kan geven. 
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Bij ernstige bacteriele infecties zoals bloedvergiftiging treden er in het 
lichaam heftige ontstekingsreacties op, die uiteindelijk schadelijk voor de 
organen kunnen zijn. In deze situaties zijn IL-12 bloedspiegels vaak hoog. We 
bestudeerden daarom of IL-12 ontstekingseffecten tot gevolg heeft (hoofdstuk 
5). IL-12 bleek, in de dosis die voor fase II onderzoek geadviseerd werd, 
inderdaad een stimulus voor gegeneraliseerde ontstekingseffecten te zijn. Bij 
lagere doseringen was dit nauwelijks het geval. 
De eerste fase II studie met IL-12 is inmiddels in andere onderzoekscentra 
bij patienten met uitgezaaide niercel kanker uitgevoerd. Helaas bleek IL-12 niet 
werkzaam. Het ontbreken van anti-tumor effecten lijkt gerelateerd aan de 
uitdoving van immunoiogische effecten die door ons werd waargenomen bij 
herhaalde IL-12 injectie. 
Wij veronderstellen dat in het menselijk lichaam feedback mechanismen in 
werking treden, zoals bijvoorbeeld productie van IL-10, in antwoord op de 
potentieel schadelijke ontstekingseffecten die door ons werden waargenomen na 
relatief hoge dosering IL-12. 
Recent onderzoek toont aan dat IL-12 desondanks een belangrijk 
immunotherapeutisch middel kan worden. Kanker vaccinatie is een andere vorm 
van immunotherapie waarnaar op dit moment wereldwijd veel onderzoek wordt 
gedaan. Vaccins tegen kanker bestaan vaak uit eiwitten afkomstig van 
kankercellen, waaraan een hulpstof is toegevoegd die de afweer tegen deze 
eiwitten moet stimuleren. Een dergelijke hulpstof heet een adjuvans. Elders 
uitgevoerde studies in proefdieren en patienten hebben nu aangetoond dat IL-12 
krachtige adjuvante effecten heeft. Hoofdstuk 6 geeft hiervan een overzicht. 
Omdat aile klassieke adjuvante stoffen lokale ontsteking veroorzaken, lijken de 
ontstekingseffecten van IL-12 een belangrijke rol te spelen bij de adjuvante 
werking. In lage doseringen blijkt IL-12 het meest werkzaam als adjuvans. 
Conclusie 
Bij herhaalde toediening van relatief hoge doseringen IL-12 doven de 
immunologische effecten van IL-12 uit. Dit is vermoedelijk de oorzaak van de 
teleurstellende behandelingsresultaten in fase II onderzoek. Recent hebben 
kanker vaccinatie studies aangetoond dat IL-12 in lage doseringen een krachtige 
adjuvante werking heeft. Lokale ontstekingseffecten lijken hierbij van groat 
belang te zijn. Echter, wij toonden aan dat hoge doseringen IL-12 tot 
gegeneraliseerde ontstekingseffecten kunnen leiden. Deze potentieel schadelijke 
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reacties activeren waarschijnlijk feedback mechanismen die de therapeutische 
effecten van IL-12 teniet kunnen doen. 
IL-12 is een veelbelovend adjuvans voor kanker vaccinaties, en in lage dosis 
waarschijnlijk het meest effectief. 
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